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reamble
primary challenge in the development of clinical practice
uidelines is keeping pace with the stream of new data on
hich recommendations are based. In an effort to respond
ore quickly to new evidence, the American College of
ardiology Foundation/American Heart Association
ACCF/AHA) Task Force on Practice Guidelines has
reated a “focused update” process to revise the existing
uideline recommendations that are affected by the evolving
ata or opinion. Prior to the initiation of this focused
pproach, periodic updates and revisions of existing guidelines
equired up to 3 years to complete. Now, however, new
vidence is reviewed in an ongoing fashion to more efficiently
espond to important science and treatment trends that could
ave a major impact on patient outcomes and quality of care.
vidence is reviewed at least twice a year, and updates will be
nitiated on an as-needed basis as quickly as possible, while
aintaining the rigorous methodology that the ACCF and
HA have developed during their more than 20 years of
artnership.
These updated guideline recommendations reflect a con-
ensus of expert opinion after a thorough review primarily of
ate-breaking clinical trials identified through a broad-based
etting process as important to the relevant patient popu-
ation, as well as of other new data deemed to have an
mpact on patient care (see Section 1.1., Evidence Review,
or details regarding this focused update). It is important to
ote that this focused update is not intended to represent
n update based on a full literature review from the date
f the previous guideline publication. Specific criteria/
onsiderations for inclusion of new data include the following:
•
•
•
•
•
•
•
•
•
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Large randomized, placebo-controlled trial(s)
Nonrandomized data deemed important on the basis of
results affecting current safety and efficacy assumptions
Strength/weakness of research methodology and findings
Likelihood of additional studies influencing current findings
Impact on current performance measure(s) and/or like-
lihood of need to develop new performance measure(s)
Requests and requirements for review and update from the
practice community, key stakeholders, and other sources
free of relationships with industry or other potential bias
Number of previous trials showing consistent results
Need for consistency with a new guideline or guideline
revision
In analyzing the data and developing updated recommen-
ations and supporting text, the focused update writing
roup used evidence-based methodologies developed by the
CCF/AHA Task Force on Practice Guidelines, which are
escribed elsewhere (1).
The schema for class of recommendation and level of
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpop
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when wr
complete thought, such that a recommendation, even if separated and presented apart from
ull intent of the recommendation. It is hoped that this will increase readers’ comprehension ofvidence is summarized in Table 1, which also illustrates iow the grading system provides an estimate of the size of
he treatment effect and an estimate of the certainty of the
reatment effect. Note that a recommendation with Level of
vidence B or C does not imply that the recommendation
s weak. Many important clinical questions addressed in
uidelines do not lend themselves to clinical trials. Although
andomized trials may not be available, there may be a very
lear clinical consensus that a particular test or therapy is
seful and effective. Both the class of recommendation and
evel of evidence listed in the focused updates are based on
onsideration of the evidence reviewed in previous iterations
f the guideline as well as the focused update. Of note, the
mplications of older studies that have informed recommen-
ations but have not been repeated in contemporary settings
re carefully considered.
The ACCF/AHA practice guidelines address patient
opulations (and healthcare providers) residing in North
merica. As such, drugs that are not currently available
n North America are discussed in the text without a
pecific class of recommendation. For studies performed
vidence
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
commendations. All guideline recommendations have been written in full sentences that express
t of the document (including headings above sets of recommendations), would still convey the
idelines and will allow quires at the individual recommendation level.l of E
ulations
at the r
e a ver
iting ren large numbers of subjects outside of North America,
e
d
t
p
s
a
d
d
o
t
T
m
a
c
b
q
p
r
o
r
t
a
m
t
m
c
r
m
a
d
o
2
c
n
i
t
n
h
m
a
r
a
r
e
g
c
t
p
A
t
(
c
2
C
i
t
e
h
1
1
L
a
a
o
c
e
i
c
o
e
G
C
g
t
(
H
h
u
i
t
Q
p
t
T
i
t
s
A
a
s
t
w
m
f
I
t
1346 Jessup et al. JACC Vol. 53, No. 15, 2009
2009 Guideline Focused Update on Heart Failure April 14, 2009:1343–82ach writing committee reviews the potential impact of
ifferent practice patterns and patient populations on the
reatment effect and on the relevance to the ACCF/AHA target
opulation to determine whether the findings should inform a
pecific recommendation.
The ACCF/AHA practice guidelines are intended to
ssist healthcare providers in clinical decision making by
escribing a range of generally acceptable approaches for the
iagnosis, management, and prevention of specific diseases
r conditions. The guidelines attempt to define practices
hat meet the needs of most patients in most circumstances.
he ultimate judgment regarding care of a particular patient
ust be made by the healthcare provider and patient in light of
ll the circumstances presented by that patient. Thus, there are
ircumstances in which deviations from these guidelines may
e appropriate. Clinical decision making should consider the
uality and availability of expertise in the area where care is
rovided. These guidelines may be used as the basis for
egulatory or payer decisions, but the ultimate goals are quality
f care and serving the patient’s best interests.
Prescribed courses of treatment in accordance with these
ecommendations are effective only if they are followed by
he patient. Because lack of patient adherence may adversely
ffect treatment outcomes, healthcare providers should
ake every effort to engage the patient in active participa-
ion with prescribed treatment.
The ACCF/AHA Task Force on Practice Guidelines
akes every effort to avoid actual, potential, or perceived
onflict of interest that may arise as a result of industry
elationships or personal interests among the writing com-
ittee. Specifically, all members of the writing committee,
s well as peer reviewers of the document, are asked to
isclose all such relationships pertaining to the trials and
ther evidence under consideration (see Appendixes 1 and
). Final recommendations were balloted to all writing
ommittee members. Writing committee members with sig-
ificant (greater than $10 000) relevant relationships with
ndustry were required to recuse themselves from voting on
hat recommendation. Writing committee members who did
ot participate are not listed as authors of this focused update.
With the exception of the recommendations presented
ere, the full guideline remains current. Only the recom-
endations from the affected section(s) of the full guideline
re included in this focused update. For easy reference, all
ecommendations from any section of a guideline affected by
change are presented with notation as to whether they
emain current, are new, or have been modified. When
vidence affects recommendations in more than 1 set of
uidelines, those guidelines are updated concurrently.
The recommendations in this focused update are considered
urrent until they are superseded by another focused update or
he full-text guidelines are revised. This focused update is
ublished in the April 14, 2009, issues of the Journal of the
merican College of Cardiology and Circulation as an update to
he full-text guideline and is also posted on the ACCF
www.acc.org, www.cardiosource.com) and AHA (my.ameri- Aanheart.org) Web sites. A revised version of the ACC/AHA
005 Guideline Update for the Diagnosis and Management of
hronic Heart Failure in the Adult (2) full-text guideline that
ncorporates the focused update has also been e-published in
hese issues and is available on the respective Web sites (3). For
asy reference, that online-only version denotes sections that
ave been updated.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA
Vice-Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Evidence Review
ate-breaking clinical trials presented at the 2005, 2006,
nd 2007 annual scientific meetings of the ACCF, AHA,
nd European Society of Cardiology, as well as selected
ther data, were reviewed by the standing guideline writing
ommittee along with the parent task force and other
xperts to identify those trials and other key data that might
mpact guideline recommendations. On the basis of the
riteria/considerations noted earlier, recent trial data and
ther clinical information were considered important
nough to prompt a focused update of the ACC/AHA 2005
uideline Update for the Diagnosis and Management of
hronic Heart Failure in the Adult (2). In addition, the
uidelines writing committee thought that a new section on
he management of the hospitalized patient with heart failure
HF) should be included in this update. A number of recent
F trials reviewed for this update, were, in fact, performed on
ospitalized patients, and a number of newer therapies are
nder development for this population. Moreover, there is
ncreasing government and other third-party payer interest in
he prevention of HF hospitalizations, and rehospitalizations.
uality indicators about the process of discharging the HF
atient have already been developed, and data about rehospi-
alizations for HF by hospital have already been made public.
hus, the committee thought that a new section about this
mportant aspect of HF care should be added to this update.
When considering the new data for this focused update,
he writing group faced the task of weighing evidence from
tudies enrolling large numbers of subjects outside North
merica. While noting that practice patterns and the rigor
pplied to data collection, as well as the genetic makeup of
ubjects, might influence the observed magnitude of a
reatment’s effect, the writing group believed that the data
ere relevant to formulation of recommendations for the
anagement of HF in North America.
Policy on clinical areas not covered by the present
ocused update can be found in the 2009 Focused Update
ncorporated into the ACC/AHA 2005 Guidelines for
he Diagnosis and Management of Heart Failure in
dults (3).
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April 14, 2009:1343–82 2009 Guideline Focused Update on Heart Failure.2. Organization of Committee and
elationships With Industry
or this focused update, all members of the 2005 HF
riting committee were invited to participate; those who
greed (referred to as the 2009 Focused Update Writing
roup) were required to disclose all relationships with
ndustry relevant to the data under consideration (1). Each
ecommendation required a confidential vote by the writing
roup members before and after external review of the
ocument. Writing group members who had a significant
greater than $10 000) relationship with industry relevant to
recommendation were required to recuse themselves from
oting on that recommendation.
.3. Review and Approval
his document was reviewed by 2 external reviewers nom-
nated by the ACCF and 2 external reviewers nominated by
he AHA, as well as a reviewer from the ACCF/AHA Task
orce on Practice Guidelines, 10 organizational reviewers
epresenting the American College of Chest Physicians, the
merican College of Physicians, the American Academy
f Family Physicians, the Heart Failure Society of Amer-
ca, and the International Society for Heart and Lung
ransplantation, and 14 individual content reviewers. All
igure 1. Stages in the Development of Heart Failure/Recommend
CEI indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor
re; LVH, left ventricular hypertrophy; and MI, myocardial infarction.nformation about reviewers’ relationships with industry Las collected and distributed to the writing committee
nd is published in this document (see Appendix 2 for
etails).
This document was approved for publication by the govern-
ng bodies of the ACCF and the AHA and endorsed by the
nternational Society for Heart and Lung Transplantation.
.4. Stages of Heart Failure:
nformation From the 2005 Guideline
he HF writing committee previously developed a new
pproach to the classification of HF (2), one that empha-
ized both the development and progression of the disease.
n doing so, they identified 4 stages involved in the
evelopment of the HF syndrome (Figure 1). The first 2
tages (A and B) are clearly not HF but are an attempt to
elp healthcare providers with the early identification of
atients who are at risk for developing HF. Stages A and B
atients are best defined as those with risk factors that
learly predispose toward the development of HF. For
xample, patients with coronary artery disease, hyperten-
ion, or diabetes mellitus who do not yet demonstrate
mpaired left ventricular (LV) function, hypertrophy, or
eometric chamber distortion would be considered Stage A,
hereas patients who are asymptomatic but demonstrate
herapy by Stage
er; EF, ejection fraction; FHx CM, family history of cardiomyopathy; HF, heart fail-ed T
blockV hypertrophy and/or impaired LV function would be
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2009 Guideline Focused Update on Heart Failure April 14, 2009:1343–82esignated as Stage B. Stage C then denotes patients with
urrent or past symptoms of HF associated with underlying
tructural heart disease (the bulk of patients with HF), and
tage D designates patients with truly refractory HF who
ight be eligible for specialized, advanced treatment strat-
gies, such as mechanical circulatory support, procedures to
acilitate fluid removal, continuous inotropic infusions, or
ardiac transplantation or other innovative or experimental. Initial and Serial Clinical Assessment of
atients Presenting With Heart Failure
he changes in this section are made to clarify the role of
unctional assessment of the HF patient, beyond the New York
eart Association (NYHA) classification, and to expand on the
se of B-type natriuretic peptide (BNP) and N-terminal
ro-B-type natriuretic peptide (NT-proBNP) testing withinurgical procedures, or for end-of-life care, such as hospice. the context of the overall evaluation of the patient (Table 2).
able 2. Updates to Section 3. Initial and Serial Clinical Assessment of Patients Presenting With Heart Failure
2005 Guideline Recommendations 2009 Focused Update Recommendations Comments
3. Recommendations for the Initial Clinical Assessment of Patients Presenting With Heart Failure
Class I
thorough history and physical examination should be
obtained/performed in patients presenting with HF to
identify cardiac and noncardiac disorders or behaviors that
might cause or accelerate the development or progression of
HF. (Level of Evidence: C)
1. A thorough history and physical examination should be
obtained/performed in patients presenting with HF to
identify cardiac and noncardiac disorders or behaviors
that might cause or accelerate the development or
progression of HF. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
careful history of current and past use of alcohol, illicit drugs,
current or past standard or “alternative therapies,” and
chemotherapy drugs should be obtained from patients
presenting with HF. (Level of Evidence: C)
2. A careful history of current and past use of alcohol, illicit
drugs, current or past standard or “alternative
therapies,” and chemotherapy drugs should be obtained
from patients presenting with HF. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
n patients presenting with HF, initial assessment should be
made of the patient’s ability to perform routine and desired
activities of daily living. (Level of Evidence: C)
3. In patients presenting with HF, initial assessment should
be made of the patient’s ability to perform routine and
desired activities of daily living. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
nitial examination of patients presenting with HF should
include assessment of the patient’s volume status,
orthostatic blood pressure changes, measurement of weight
and height, and calculation of body mass index. (Level of
Evidence: C)
4. Initial examination of patients presenting with HF should
include assessment of the patient’s volume status,
orthostatic blood pressure changes, measurement of
weight and height, and calculation of body mass index.
(Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
nitial laboratory evaluation of patients presenting with HF
should include complete blood count, urinalysis, serum
electrolytes (including calcium and magnesium), blood urea
nitrogen, serum creatinine, fasting blood glucose
(glycohemoglobin), lipid profile, liver function tests, and
thyroid-stimulating hormone. (Level of Evidence: C)
5. Initial laboratory evaluation of patients presenting with HF
should include complete blood count, urinalysis, serum
electrolytes (including calcium and magnesium), blood
urea nitrogen, serum creatinine, fasting blood glucose
(glycohemoglobin), lipid profile, liver function tests, and
thyroid-stimulating hormone. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
welve-lead electrocardiogram and chest radiograph (posterior to
anterior [PA] and lateral) should be performed initially in all
patients presenting with HF. (Level of Evidence: C)
6. Twelve-lead electrocardiogram and chest radiograph (PA
and lateral) should be performed initially in all patients
presenting with HF. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
wo-dimensional echocardiography with Doppler should be
performed during initial evaluation of patients presenting
with HF to assess left ventricular ejection fraction (LVEF),
LV size, wall thickness, and valve function. Radionuclide
ventriculography can be performed to assess LVEF and
volumes. (Level of Evidence: C)
7. Two-dimensional echocardiography with Doppler should
be performed during initial evaluation of patients
presenting with HF to assess LVEF, left ventricular size,
wall thickness, and valve function. Radionuclide
ventriculography can be performed to assess LVEF and
volumes. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
oronary arteriography should be performed in patients
presenting with HF who have angina or significant ischemia
unless the patient is not eligible for revascularization of any
kind. (Level of Evidence: B)
8. Coronary arteriography should be performed in patients
presenting with HF who have angina or significant
ischemia unless the patient is not eligible for
revascularization of any kind (4–8). (Level of Evidence: B)
2005 recommendation remains
current in the 2009 update.
Class IIa
oronary arteriography is reasonable for patients presenting
with HF who have chest pain that may or may not be of
cardiac origin who have not had evaluation of their coronary
anatomy and who have no contraindications to coronary
revascularization. (Level of Evidence: C)
1. Coronary arteriography is reasonable for patients
presenting with HF who have chest pain that may or
may not be of cardiac origin who have not had
evaluation of their coronary anatomy and who have no
contraindications to coronary revascularization. (Level of
Evidence: C)
2005 recommendation remains
current in the 2009 update.
oronary arteriography is reasonable for patients presenting with
HF who have known or suspected coronary artery disease but
who do not have angina unless the patient is not eligible for
revascularization of any kind. (Level of Evidence: C)
2. Coronary arteriography is reasonable for patients
presenting with HF who have known or suspected
coronary artery disease but who do not have angina
unless the patient is not eligible for revascularization of
any kind. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
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2005 Guideline Recommendations 2009 Focused Update Recommendations Comments
Class IIa (Continued)
oninvasive imaging to detect myocardial ischemia and
viability is reasonable in patients presenting with HF who
have known coronary artery disease and no angina unless
the patient is not eligible for revascularization of any kind.
(Level of Evidence: B)
3. Noninvasive imaging to detect myocardial ischemia and
viability is reasonable in patients presenting with HF who
have known coronary artery disease and no angina
unless the patient is not eligible for revascularization of
any kind (9). (Level of Evidence: B)
2005 recommendation remains
current in the 2009 update.
aximal exercise testing with or without measurement of
respiratory gas exchange and/or blood oxygen saturation is
reasonable in patients presenting with HF to help determine
whether HF is the cause of exercise limitation when the
contribution of HF is uncertain. (Level of Evidence: C)
4. Maximal exercise testing with or without measurement
of respiratory gas exchange and/or blood oxygen
saturation is reasonable in patients presenting with HF
to help determine whether HF is the cause of exercise
limitation when the contribution of HF is uncertain.
(Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
aximal exercise testing with measurement of respiratory gas
exchange is reasonable to identify high-risk patients
presenting with HF who are candidates for cardiac
transplantation or other advanced treatments. (Level of
Evidence: B)
5. Maximal exercise testing with measurement of
respiratory gas exchange is reasonable to identify high-
risk patients presenting with HF who are candidates for
cardiac transplantation or other advanced treatments
(10–12). (Level of Evidence: B)
2005 recommendation remains
current in the 2009 update.
creening for hemochromatosis, sleep-disturbed breathing, or
human immunodeficiency virus is reasonable in selected
patients who present with HF. (Level of Evidence: C)
6. Screening for hemochromatosis, sleep-disturbed
breathing, or human immunodeficiency virus is
reasonable in selected patients who present with HF.
(Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
iagnostic tests for rheumatologic diseases, amyloidosis, or
pheochromocytoma are reasonable in patients presenting
with HF in whom there is a clinical suspicion of these
diseases. (Level of Evidence: C)
7. Diagnostic tests for rheumatologic diseases,
amyloidosis, or pheochromocytoma are reasonable in
patients presenting with HF in whom there is a clinical
suspicion of these diseases. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
ndomyocardial biopsy can be useful in patients presenting
with HF when a specific diagnosis is suspected that would
influence therapy. (Level of Evidence: C)
8. Endomyocardial biopsy can be useful in patients
presenting with HF when a specific diagnosis is
suspected that would influence therapy (13). (Level of
Evidence: C)
2005 recommendation remains
current in the 2009 update.
easurement of BNP can be useful in the evaluation of
patients presenting in the urgent care setting in whom the
clinical diagnosis of HF is uncertain. (Level of Evidence: A)
9. Measurement of natriuretic peptides (BNP and NT-
proBNP) can be useful in the evaluation of patients
presenting in the urgent care setting in whom the
clinical diagnosis of HF is uncertain. Measurement of
natriuretic peptides (BNP and NT-proBNP) can be useful
in risk stratification (14–21). (Level of Evidence: A)
Modified recommendation
(added a caveat on
natriuretic peptides and their
role as part of total
evaluation, in both diastolic
and systolic dysfunction).
Class IIb
oninvasive imaging may be considered to define the
likelihood of coronary artery disease in patients with HF and
LV dysfunction. (Level of Evidence: C)
1. Noninvasive imaging may be considered to define the
likelihood of coronary artery disease in patients with HF
and LV dysfunction. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
olter monitoring might be considered in patients presenting
with HF who have a history of myocardial infarction (MI) and
are being considered for electrophysiologic study to
document ventricular tachycardia (VT) inducibility. (Level of
Evidence: C)
2. Holter monitoring might be considered in patients
presenting with HF who have a history of MI and are
being considered for electrophysiologic study to
document VT inducibility. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
Class III
ndomyocardial biopsy should not be performed in the routine
evaluation of patients with HF. (Level of Evidence: C)
1. Endomyocardial biopsy should not be performed in the
routine evaluation of patients with HF (13). (Level of
Evidence: C)
2005 recommendation remains
current in the 2009 update.
outine use of signal-averaged electrocardiography is not
recommended for the evaluation of patients presenting with
HF. (Level of Evidence: C)
2. Routine use of signal-averaged electrocardiography is
not recommended for the evaluation of patients
presenting with HF. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
outine measurement of circulating levels of neurohormones
(e.g., norepinephrine or endothelin) is not recommended for
patients presenting with HF. (Level of Evidence: C)
3. Routine measurement of circulating levels of
neurohormones (e.g., norepinephrine or endothelin) is
not recommended for patients presenting with HF.
(Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
3. Recommendations for Serial Clinical Assessment of Patients Presenting With Heart Failure
Class I
ssessment should be made at each visit of the ability of a
patient with HF to perform routine and desired activities of
daily living. (Level of Evidence: C)
1. Assessment should be made at each visit of the ability
of a patient with HF to perform routine and desired
activities of daily living. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
ssessment should be made at each visit of the volume status
and weight of a patient with HF. (Level of Evidence: C)
2. Assessment should be made at each visit of the volume
status and weight of a patient with HF. (Level of
Evidence: C)
2005 recommendation remains
current in the 2009 update.
areful history of current use of alcohol, tobacco, illicit drugs,
“alternative therapies,” and chemotherapy drugs, as well as
diet and sodium intake, should be obtained at each visit of a
patient with HF. (Level of Evidence: C)
3. Careful history of current use of alcohol, tobacco, illicit
drugs, “alternative therapies,” and chemotherapy drugs,
as well as diet and sodium intake, should be obtained at
each visit of a patient with HF. (Level of Evidence: C)
2005 recommendation remains
current in the 2009 update.
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.1.1. Identification of Patients
n general, patients with LV dysfunction or HF present to
he healthcare provider in 1 of 3 ways:
. With a syndrome of decreased exercise tolerance. Most
patients with HF seek medical attention with complaints of
a reduction in their effort tolerance due to dyspnea and/or
fatigue. These symptoms, which may occur at rest or during
exercise, may be attributed inappropriately by the patient
and/or healthcare provider to aging, other physiological
abnormalities (e.g., deconditioning), or other medical dis-
orders (e.g., pulmonary disease). Therefore, in a patient
whose exercise capacity is limited by dyspnea or fatigue, the
healthcare provider must determine whether the principal
cause is HF or another abnormality. Elucidation of the
precise reason for exercise intolerance can be difficult
because several disorders may coexist in the same patient. A
clear distinction can sometimes be made only by measure-
ments of gas exchange or blood oxygen saturation or by
invasive hemodynamic measurements during graded levels
of exercise (see ACC/AHA 2002 Guideline Update for
Exercise Testing [22]).
. With a syndrome of fluid retention. Patients may present
with complaints of leg or abdominal swelling as their
primary (or only) symptom. In these patients, the impair-
ment of exercise tolerance may occur so gradually that it
may not be noted unless the patient is questioned carefully
and specifically about a change in activities of daily living.
. With no symptoms or symptoms of another cardiac or
noncardiac disorder. During their evaluation for a
disorder other than HF (e.g., abnormal heart sounds or
abnormal electrocardiogram or chest x-ray, hypertension
or hypotension, diabetes mellitus, an acute myocardial
infarction (MI), an arrhythmia, or a pulmonary or
systemic thromboembolic event), patients may be found
to have evidence of cardiac enlargement or dysfunction.
A variety of approaches have been used to quantify the
egree of functional limitation imposed by HF. The most
idely used scale is the NYHA functional classification (23),
able 2. Continued
2005 Guideline Recommendations 200
Cl
epeat measurement of ejection fraction (EF) and the severity
of structural remodeling can provide useful information in
patients with HF who have had a change in clinical status or
who have experienced or recovered from a clinical event or
received treatment that might have had a significant effect
on cardiac function. (Level of Evidence: C)
1. Repeat m
remodeli
patients
status or
clinical e
a signific
Evidence
Cl
he value of serial measurements of BNP to guide therapy for
patients with HF is not well established. (Level of Evidence: C)
1. The value
therapy f
(Level ofut this system is subject to considerable interobserver variabil- cty and is insensitive to important changes in exercise capacity.
hese limitations may be overcome by formal tests of exercise
olerance. Measurement of the distance that a patient can walk
n 6 minutes may have prognostic significance and may help to
ssess the level of functional impairment in the very sick, but
erial changes in walking distance may not parallel changes in
linical status. Maximal exercise testing, with measurement of
eak oxygen uptake, has been used to identify appropriate
andidates for cardiac transplantation, to determine disability,
nd to assist in the formulation of an exercise prescription, but
ts role in the general management of patients with HF has not
een defined.
.1.2. Identification of a Structural and Functional
bnormality
complete history and physical examination are the first steps
n evaluating the structural abnormality or cause responsible for
he development of HF. Direct inquiry may reveal prior or
urrent evidence of MI, valvular disease, or congenital heart
isease, whereas examination of the heart may suggest the
resence of cardiac enlargement, murmurs, or a third heart
ound. Although the history and physical examination may
rovide important clues about the nature of the underlying
ardiac abnormality, identification of the structural abnormal-
ty leading to HF generally requires invasive or noninvasive
maging of the cardiac chambers or great vessels.
The single most useful diagnostic test in the evaluation of
atients with HF is the comprehensive 2-dimensional echo-
ardiogram coupled with Doppler flow studies to determine
hether abnormalities of myocardium, heart valves, or pericar-
ium are present and which chambers are involved. Three
undamental questions must be addressed: 1) Is the LV
jection fraction (EF) preserved or reduced? 2) Is the structure
f the LV normal or abnormal? 3) Are there other structural
bnormalities such as valvular, pericardial, or right ventricular
bnormalities that could account for the clinical presentation?
his information should be quantified with a numerical esti-
ate of EF, measurement of ventricular dimensions and/or
olumes, measurement of wall thickness, and evaluation of
used Update Recommendations Comments
a
rement of EF and the severity of structural
be useful to provide information in
F who have had a change in clinical
ave experienced or recovered from a
r received treatment that might have had
fect on cardiac function. (Level of
2005 recommendation remains
current in the 2009 update.
b
rial measurements of BNP to guide
ients with HF is not well established.
ce: C)
2005 recommendation remains
current in the 2009 update.9 Foc
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ssessed. Atrial size should also be determined semiquantita-
ively and left atrial dimensions and/or volumes measured. All
alves should be evaluated for anatomic and flow abnormalities
o exclude the presence of primary valve disease. Secondary
hanges in valve function, particularly the severity of mitral and
ricuspid valve insufficiency, should be determined.
Noninvasive hemodynamic data acquired at the time of
chocardiography are an important additional correlate for
atients with preserved or reduced EF. Combined quantifica-
ion of the mitral valve inflow pattern, pulmonary venous
nflow pattern, and mitral annular velocity provides data about
haracteristics of LV filling and left atrial pressure. Evaluation
f the tricuspid valve regurgitant gradient coupled with mea-
urement of inferior vena caval dimension and its response
uring respiration provides an estimate of systolic pulmonary
rtery pressure and central venous pressure. Stroke volume may
e determined with combined dimension measurement and
ulsed Doppler in the LV outflow tract (24). However,
bnormalities can be present in any of these parameters in the
bsence of HF. No single parameter necessarily correlates
pecifically with HF; however, a totally normal filling pattern
rgues against clinical HF.
A comprehensive echocardiographic evaluation is impor-
ant, because it is common for patients to have more than 1
ardiac abnormality that contributes to the development of
F. Furthermore, the study may serve as a baseline for
omparison, because measurement of EF and the severity of
tructural remodeling can provide useful information in pa-
ients who have had a change in clinical status or who have
xperienced or recovered from a clinical event or received
reatment that might have had a significant effect on cardiac
unction.
Other tests may be used to provide information regarding
he nature and severity of the cardiac abnormality. Radio-
uclide ventriculography can provide highly accurate mea-
urements of LV function and right ventricular EF, but it is
nable to directly assess valvular abnormalities or cardiac
ypertrophy. Magnetic resonance imaging or computed
omography may be useful in evaluating chamber size and
entricular mass, detecting right ventricular dysplasia, or
ecognizing the presence of pericardial disease, as well as in
ssessing cardiac function and wall motion (25).
Magnetic resonance imaging may also be used to identify
yocardial viability and scar tissue (26). Chest radiography can
e used to estimate the degree of cardiac enlargement and
ulmonary congestion or to detect the presence of pulmonary
isease. A 12-lead electrocardiogram may demonstrate evi-
ence of prior MI, LV hypertrophy, cardiac conduction ab-
ormality (e.g., left bundle-branch block), or a cardiac arrhyth-
ia. However, because of their low sensitivity and specificity,
either the chest x-ray nor the electrocardiogram should form
he primary basis for determining the specific cardiac abnor-
ality responsible for the development of HF. i.1.3.2. LABORATORY TESTING
aboratory testing may reveal the presence of disorders or
onditions that can lead to or exacerbate HF. The initial
valuation of patients with HF should include a complete
lood count, urinalysis, serum electrolytes (including cal-
ium and magnesium), glycohemoglobin, and blood lipids,
s well as tests of both renal and hepatic function, a chest
adiograph, and a 12-lead electrocardiogram. Thyroid func-
ion tests (especially thyroid-stimulating hormone) should
e measured, because both hyperthyroidism and hypothy-
oidism can be a primary or contributory cause of HF. A
asting transferrin saturation is useful to screen for hemo-
hromatosis; several mutated alleles for this disorder are
ommon in individuals of Northern European descent, and
ffected patients may show improvement in LV function
fter treatment with phlebotomy and chelating agents.
agnetic resonance imaging of the heart or liver may be
eeded to confirm the presence of iron overload. Screening
or human immunodeficiency virus (HIV) is reasonable and
hould be considered for all high-risk patients. However,
ther clinical signs of HIV infection typically precede any
F symptoms in those patients who develop HIV cardio-
yopathy. Serum titers of antibodies developed in response
o infectious organisms are occasionally measured in pa-
ients with a recent onset of HF (especially in those with a
ecent viral syndrome), but the yield of such testing is low,
nd the therapeutic implications of a positive result are
ncertain (see a recent review of the role of endomyocardial
iopsy (13), and Section 3.1.3.4, Evaluation of the Possi-
ility of Myocardial Disease, in the full-text guideline.
ssays for connective tissue diseases and for pheochromo-
ytoma should be performed if these diagnoses are sus-
ected, and serum titers of Chagas disease antibodies should
e checked in patients with nonischemic cardiomyopathy
ho have traveled in or emigrated from an endemic region.
Several recent assays have been developed for natriuretic
eptides (BNP and NT-proBNP). Several of the natriuretic
eptides are synthesized by and released from the heart.
levated plasma BNP levels have been associated with
educed LVEF (27), LV hypertrophy, elevated LV filling
ressures, and acute MI and ischemia, although they can
ccur in other settings, such as pulmonary embolism and
hronic obstructive pulmonary disease.
Natriuretic peptides are sensitive to other biological factors,
uch as age, sex, weight, and renal function (28). Elevated
evels lend support to a diagnosis of abnormal ventricular
unction or hemodynamics causing symptomatic HF (29).
rials with these diagnostic markers suggest use in the urgent-
are setting, where they have been used in combination with
linical evaluation to differentiate dyspnea due to HF from
yspnea of other causes (4), and suggest that its use may reduce
oth the time to hospital discharge and the cost of treatment
30). BNP levels tend to be less elevated in HF with preserved
F than in HF with low EF and are lower in obese patients
31,32). Levels of natriuretic peptides may be elevated mean-
ngfully in women and in people over 60 years of age who do
n
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autiously in such individuals when distinguishing between
ardiac and noncardiac causes of dyspnea. Elevated natriuretic
eptide levels may lend weight to a suspected diagnosis of HF
r trigger consideration of HF when the diagnosis is unknown
ut should not be used in isolation to confirm or exclude the
resence of HF (30,33).
.2.3. Laboratory Assessment
erum electrolytes and renal function should be monitored
outinely in patients with HF. Of particular importance is
he serial measurement of serum potassium concentration,
ecause hypokalemia is a common adverse effect of treat-
ent with diuretics and may cause fatal arrhythmias and
ncrease the risk of digitalis toxicity, whereas hyperkalemia
ay complicate therapy with angiotensin-converting en-
yme (ACE) inhibitors, angiotensin II receptor blockers
ARBs), and aldosterone antagonists. Worsening renal
unction may require adjustment of the doses of diuretics,
enin-angiotensin-aldosterone system antagonists, digoxin,
nd noncardiac medications. Development of hyponatremia
r anemia may be a sign of disease progression and is
ssociated with impaired survival.
Serum BNP levels have been shown to parallel the clinical
everity of HF as assessed by NYHA class in broad
opulations. Levels are higher in hospitalized patients and
end to decrease during aggressive therapy for decompen-
ation (see Section 3.1.3.2. in the full-text guideline, Lab-
ratory Testing) (29). Indeed, there is an increasing body of
vidence demonstrating the power of the addition of BNP
or NT-proBNP) levels in the assessment of prognosis in a
ariety of cardiovascular disorders. However, it cannot be
ssumed that BNP levels can be used effectively as targets
or adjustment of therapy in individual patients. Many
atients taking optimal doses of medications continue to
how markedly elevated levels of BNP, and some patients
emonstrate BNP levels within the normal range despite
dvanced HF. The use of BNP measurements to guide the
itration of drug doses has not been shown conclusively to
mprove outcomes more effectively than achievement of the
arget doses of drugs shown in clinical trials to prolong life
34). Ongoing trials will help to determine the role of serial
NP (or other natriuretic peptides) measurements in both
iagnosis and management of HF.
Serial chest radiographs are not recommended in the
anagement of chronic HF. Although the cardiothoracic
atio is commonly believed to reflect the cardiac dilatation
hat is characteristic of HF, enlargement of the cardiac
ilhouette primarily reflects changes in right ventricular
olume rather than LV function, because the right ventricle
orms most of the border of dilated hearts on radiographs.
imilarly, changes in the radiographic assessment of pulmo-
ary vascular congestion are too insensitive to detect any but
he most extreme changes in fluid status (35).
Repeat assessment of EF may be most useful when the
atient has demonstrated a major change in clinical status. aoth improvement and deterioration may have important
mplications for future care, although the recommended
edical regimen should be continued in most cases. Im-
rovement may reflect recovery from a previous condition,
uch as viral myocarditis or hypothyroidism, or may occur
fter titration of recommended therapies for chronic HF.
hus, it is appropriate to obtain a repeat EF after some
eriod of optimal medical therapy, typically 4 to 6 months,
o decide about the implantation of an implantable
ardioverter-defibrillator (ICD). Deterioration may reflect
radual disease progression or a new event, such as recurrent
I. Routine assessment of EF at frequent, regular, or
rbitrary intervals is not recommended.
There has been no established role for periodic invasive or
oninvasive hemodynamic measurements in the manage-
ent of HF. Most drugs used for the treatment of HF are
rescribed on the basis of their ability to improve symptoms
r survival rather than their effect on hemodynamic vari-
bles. Moreover, the initial and target doses of these drugs
re selected on the basis of experience in controlled trials
nd are not based on the changes they may produce in
ardiac output or pulmonary wedge pressure. Nevertheless,
nvasive hemodynamic measurements may assist in the
etermination of volume status and in distinguishing HF
rom other disorders that may cause circulatory instability,
uch as pulmonary diseases and sepsis. Measurements of
ardiac output and pulmonary wedge pressure through a
ulmonary artery catheter have also been used in patients
ith refractory HF to assess pulmonary vascular resistance,
determinant of eligibility for heart transplantation. Car-
iac output can also be measured by noninvasive methods.
.2.4. Assessment of Prognosis
lthough both healthcare providers and patients may be
nterested in defining the prognosis of an individual patient
ith HF, the likelihood of survival can be determined
eliably only in populations and not in individuals. How-
ver, some attempt at prognostication in HF may provide
etter information for patients and their families to help
hem appropriately plan for their futures. It also identifies
atients in whom cardiac transplantation or mechanical
evice therapy should be considered.
Multivariate analysis of clinical variables has helped to
dentify the most significant predictors of survival, and prog-
ostic models have been developed and validated (36). De-
reasing LVEF, worsening NYHA functional status, degree of
yponatremia, decreasing peak exercise oxygen uptake, de-
reasing hematocrit, widened QRS on 12-lead electrocardio-
ram, chronic hypotension, resting tachycardia, renal insuffi-
iency, intolerance to conventional therapy, and refractory
olume overload are all generally recognized key prognostic
arameters, although the actual prognostic models incorporat-
ng them are not widely used in clinical practice (36,37).
lthough elevated circulating levels of neurohormonal factors
ave also been associated with high mortality rates, the routine
ssessment of neurohormones such as norepinephrine or en-
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ikewise, elevated BNP (or NT-proBNP) levels predict higher
isk of HF and other events after MI, whereas marked
levation in BNP levels during hospitalization for HF may
redict rehospitalization and death. Nonetheless, the BNP
easurement has not been clearly shown to supplement careful
linical assessment for management.
Because treatment of HF has improved over the past 10
ears, the older prognostic models need to be revalidated (38),
nd newer prognostic models may have to be developed.
utcomes have been improved for most high-risk patients,
hich has resulted in a shift in the selection process for patients
eferred for heart transplantation (38). Routine use of ambu-
atory electrocardiographic monitoring, T-wave alternans anal-
sis, heart rate variability measurement, and signal-averaged
lectrocardiography have not been shown to provide incremen-
al value in assessing overall prognosis, although ambulatory
lectrocardiographic monitoring can be useful in decision
aking regarding placement of ICDs (39). fi. Therapy
.3.1. Patients With Reduced Left Ventricular
jection Fraction
hanges in this section focused on 3 areas: recommendations
bout electrical device therapy (e.g., cardiac resynchronization
herapy [CRT] and ICDs), the use of a fixed dose combination
f hydralazine and isosorbide dinitrate in self-identified African
mericans, and the management of atrial fibrillation in pa-
ients with HF. The previous version of the guidelines had a
umber of possibly confusing recommendations about selection
f patients for ICD implantation. The writing group has
ried to simplify the recommendations, and keep them con-
ordant with the most recent guidelines covering the same
ssue (39,40). Updated trial information has led to the
hange in the recommendations about the use of hydralazine/
sosorbide dinitrate and about the management of atrial
brillation (Table 3).able 3. Updates to Section 4.3.1. Patients With Reduced Lef
jection Fraction
2005 Guideline Recommendations 2009
4.3.1. Patients With Reduced
C
easures listed as Class I recommendations for patients in
stages A and B are also appropriate for patients in Stage
C. (Levels of Evidence: A, B, and C as appropriate)
1. Measures
patients
patients
appropria
iuretics and salt restriction are indicated in patients with
current or prior symptoms of HF and reduced LVEF who
have evidence of fluid retention (see Table 4). (Level of
Evidence: C)
2. Diuretics
with curr
who have
full-text g
ngiotensin converting enzyme inhibitors are recommended
for all patients with current or prior symptoms of HF and
reduced LVEF, unless contraindicated (see text, Table 3 in
the full-text guidelines). (Level of Evidence: A)
3. Angioten
recomme
symptom
contraind
guideline
eta blockers (using 1 of the 3 proven to reduce mortality,
i.e., bisoprolol, carvedilol, and sustained release
metoprolol succinate) are recommended for all stable
patients with current or prior symptoms of HF and
reduced LVEF, unless contraindicated (see text, Table 3 in
the full-text guidelines). (Level of Evidence: A)
4. Beta bloc
mortality
release m
stable pa
and redu
Table 3 in
Evidence
ngiotensin II receptor blockers approved for the
treatment of HF (see Table 3) are recommended in
patients with current or prior symptoms of HF and
reduced LVEF who are ACE inhibitor-intolerant (see text
for information regarding patients with angioedema).
(Level of Evidence: A)
5. Angioten
text guide
current o
are ACE i
regarding
Evidence
rugs known to adversely affect the clinical status of
patients with current or prior symptoms of HF and
reduced LVEF should be avoided or withdrawn whenever
possible (e.g., nonsteroidal anti-inflammatory drugs, most
antiarrhythmic drugs, and most calcium channel blocking
drugs; see text). (Level of Evidence: B)
6. Drugs kn
patients
reduced L
wheneve
drugs, m
channel b
Evidencet Ventricular
Focused Update Recommendations Comments
Left Ventricular Ejection Fraction
lass I
listed as Class I recommendations for
in stages A and B are also appropriate for
in Stage C. (Levels of Evidence: A, B, and C as
te)
2005 recommendation remains
current in 2009 update.
and salt restriction are indicated in patients
ent or prior symptoms of HF and reduced LVEF
evidence of fluid retention (see Table 4 in the
uidelines). (Level of Evidence: C)
2005 recommendation remains
current in 2009 update.
sin-converting enzyme inhibitors are
nded for all patients with current or prior
s of HF and reduced LVEF, unless
icated (see text, Table 3 in the full-text
s) (41–53). (Level of Evidence: A)
2005 recommendation remains
current in 2009 update.
kers (using 1 of the 3 proven to reduce
, i.e., bisoprolol, carvedilol, and sustained
etoprolol succinate) are recommended for all
tients with current or prior symptoms of HF
ced LVEF, unless contraindicated (see text,
the full-text guidelines) (54–72). (Level of
: A)
2005 recommendation remains
current in 2009 update.
sin II receptor blockers (see Table 3 in the full-
lines) are recommended in patients with
r prior symptoms of HF and reduced LVEF who
nhibitor-intolerant (see text for information
patients with angioedema) (73–83). (Level of
: A)
2005 recommendation remains
current but text modified to
eliminate specific agents
tested.
own to adversely affect the clinical status of
with current or prior symptoms of HF and
VEF should be avoided or withdrawn
r possible (e.g., nonsteroidal anti-inflammatory
ost antiarrhythmic drugs, and most calcium
locking drugs; see text) (84–90). (Level of
: B)
2005 recommendation remains
current in 2009 update.
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2005 Guideline Recommendations 2009 Focused Update Recommendations Comments
Class I (Continued)
aximal exercise testing with or without measurement of
respiratory gas exchange is recommended to facilitate
prescription of an appropriate exercise program for
patients with HF. (Level of Evidence: C)
2005 recommendation no
longer current. See 2009
Class IIa No. 2
recommendation below.
xercise training is beneficial as an adjunctive approach to
improve clinical status in ambulatory patients with current
or prior symptoms of HF and reduced LVEF. (Level of
Evidence: B)
7. Exercise training is beneficial as an adjunctive
approach to improve clinical status in ambulatory
patients with current or prior symptoms of HF and
reduced LVEF (90a–90d). (Level of Evidence: B)
2005 recommendation remains
current in 2009 update.
n implantable cardioverter-defibrillator is recommended as
secondary prevention to prolong survival in patients with
current or prior symptoms of HF and reduced LVEF who
have a history of cardiac arrest, ventricular fibrillation, or
hemodynamically destabilizing ventricular tachycardia.
(Level of Evidence: A)
8. An implantable cardioverter-defibrillator is
recommended as secondary prevention to prolong
survival in patients with current or prior symptoms of
HF and reduced LVEF who have a history of cardiac
arrest, ventricular fibrillation, or hemodynamically
destabilizing ventricular tachycardia (91–93). (Level of
Evidence: A)
2005 recommendation remains
current in 2009 update.
mplantable cardioverter-defibrillator therapy is
recommended for primary prevention to reduce total
mortality by a reduction in sudden cardiac death in
patients with ischemic heart disease who are at least 40
days post-MI, have an LVEF less than or equal to 30%,
with NYHA functional class II or III symptoms while
undergoing chronic optimal medical therapy, and have
reasonable expectation of survival with a good functional
status for more than 1 year. (Level of Evidence: A)
9. Implantable cardioverter-defibrillator therapy is
recommended for primary prevention of sudden
cardiac death to reduce total mortality in patients with
non-ischemic dilated cardiomyopathy or ischemic heart
disease at least 40 days post-MI, a LVEF less than or
equal to 35%, and NYHA functional class II or III
symptoms while receiving chronic optimal medical
therapy, and who have reasonable expectation of
survival with a good functional status for more than 1
year (40,93–99). (Level of Evidence: A)
Modified recommendation to be
consistent with the
ACC/AHA/Heart Rhythm
Society (HRS) 2008 Device-
Based Therapy guidelines.
mplantable cardioverter-defibrillator therapy is
recommended for primary prevention to reduce total
mortality by a reduction in sudden cardiac death in
patients with nonischemic cardiomyopathy who have an
LVEF less than or equal to 30%, with NYHA functional
class II or III symptoms while undergoing chronic optimal
medical therapy, and who have reasonable expectation of
survival with a good functional status for more than 1
year. (Level of Evidence: B)
2005 recommendation no
longer current. See 2009
Class I No. 9
recommendation above.
atients with LVEF less than or equal to 35%, sinus rhythm,
and NYHA functional class III or ambulatory class IV
symptoms despite recommended, optimal medical
therapy and who have cardiac dyssynchrony, which is
currently defined as a QRS duration greater than 120 ms,
should receive cardiac resynchronization therapy unless
contraindicated. (Level of Evidence: A)
10. Patients with LVEF of less than or equal to 35%, sinus
rhythm, and NYHA functional class III or ambulatory
class IV symptoms despite recommended, optimal
medical therapy and who have cardiac dyssynchrony,
which is currently defined as a QRS duration greater
than or equal to 0.12 seconds, should receive cardiac
resynchronization therapy, with or without an ICD, unless
contraindicated (100–115). (Level of Evidence: A)
Clarified recommendation
(includes therapy with or
without an ICD).
ddition of an aldosterone antagonist is reasonable in
selected patients with moderately severe to severe
symptoms of HF and reduced LVEF who can be carefully
monitored for preserved renal function and normal
potassium concentration. Creatinine should be less than
or equal to 2.5 mg per dL in men or less than or equal to
2.0 mg per dL in women and potassium should be less
than 5.0 mEq per liter. Under circumstances where
monitoring for hyperkalemia or renal dysfunction is not
anticipated to be feasible, the risks may outweigh the
benefits of aldosterone antagonists. (Level of Evidence: B)
11. Addition of an aldosterone antagonist is recommended
in selected patients with moderately severe to severe
symptoms of HF and reduced LVEF who can be
carefully monitored for preserved renal function and
normal potassium concentration. Creatinine should be
2.5 mg per dL or less in men or 2.0 mg per dL or less
in women and potassium should be less than 5.0
mEq per liter. Under circumstances where
monitoring for hyperkalemia or renal dysfunction is
not anticipated to be feasible, the risks may
outweigh the benefits of aldosterone antagonists
(116–118). (Level of Evidence: B)
2005 recommendation remains
current in 2009 update.
12. The combination of hydralazine and nitrates is
recommended to improve outcomes for patients self-
described as African-Americans, with moderate-severe
symptoms on optimal therapy with ACE inhibitors,
beta blockers, and diuretics (119,120). (Level of
Evidence: B)
New recommendation
Class IIa
1. It is reasonable to treat patients with atrial fibrillation
and HF with a strategy to maintain sinus rhythm or
with a strategy to control ventricular rate alone (121–
125). (Level of Evidence: A)
New recommendation
2. Maximal exercise testing with or without measurement
of respiratory gas exchange is reasonable to facilitate
prescription of an appropriate exercise program for
patients presenting with HF. (Level of Evidence: C)
Modified recommendation
(changed class of
recommendation from I to
IIa).
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Class IIa (Continued)
ngiotensin II receptor blockers are reasonable to use as
alternatives to ACE inhibitors as first-line therapy for
patients with mild to moderate HF and reduced LVEF,
especially for patients already taking ARBs for other
indications. (Level of Evidence: A)
3. Angiotensin II receptor blockers are reasonable to use
as alternatives to ACE inhibitors as first-line therapy for
patients with mild to moderate HF and reduced LVEF,
especially for patients already taking ARBs for other
indications (73–82). (Level of Evidence: A)
2005 recommendation remains
current in 2009 update.
igitalis can be beneficial in patients with current or prior
symptoms of HF and reduced LVEF to decrease
hospitalizations for HF. (Level of Evidence: B)
4. Digitalis can be beneficial in patients with current or
prior symptoms of HF and reduced LVEF to decrease
hospitalizations for HF (126–133). (Level of
Evidence: B)
2005 recommendation remains
current in 2009 update.
he addition of a combination of hydralazine and a nitrate is
reasonable for patients with reduced LVEF who are
already taking an ACE inhibitor and beta-blocker for
symptomatic HF and who have persistent symptoms.
(Level of Evidence: B)
5. The addition of a combination of hydralazine and a
nitrate is reasonable for patients with reduced LVEF
who are already taking an ACE inhibitor and beta
blocker for symptomatic HF and who have persistent
symptoms (119,134). (Level of Evidence: B)
2005 recommendation remains
current in 2009 update.
lacement of an implantable cardioverter-defibrillator is
reasonable in patients with LVEF of 30% to 35% of any
origin with NYHA functional class II or III symptoms who
are taking chronic optimal medical therapy and who have
reasonable expectation of survival with good functional
status of more than 1 year. (Level of Evidence: B)
2005 recommendation no
longer current. See 2009
Class I No. 9
recommendation above.
6. For patients who have LVEF less than or equal to 35%,
a QRS duration of greater than or equal to 0.12
seconds, and atrial fibrillation (AF), CRT with or without
an ICD is reasonable for the treatment of NYHA
functional class III or ambulatory class IV heart failure
symptoms on optimal recommended medical therapy
(3,135). (Level of Evidence: B)
New recommendation added to
be consistent with the ACC/
AHA/HRS 2008 Device-Based
Therapy guidelines (40).
7. For patients with LVEF of less than or equal to 35%
with NYHA functional class III or ambulatory class IV
symptoms who are receiving optimal recommended
medical therapy and who have frequent dependence on
ventricular pacing, CRT is reasonable (3). (Level of
Evidence: C)
New recommendation added to
be consistent with the ACC/
AHA/HRS 2008 Device-Based
Therapy guidelines.
Class IIb
combination of hydralazine and a nitrate might be
reasonable in patients with current or prior symptoms of
HF and reduced LVEF who cannot be given an ACE
inhibitor or ARB because of drug intolerance, hypotension,
or renal insufficiency. (Level of Evidence: C)
1. A combination of hydralazine and a nitrate might be
reasonable in patients with current or prior symptoms
of HF and reduced LVEF who cannot be given an ACE
inhibitor or ARB because of drug intolerance,
hypotension, or renal insufficiency (119,136,137).
(Level of Evidence: C)
2005 recommendation remains
current in 2009 update.
he addition of an ARB may be considered in persistently
symptomatic patients with reduced LVEF who are already
being treated with conventional therapy. (Level of
Evidence: B)
2. The addition of an ARB may be considered in
persistently symptomatic patients with reduced LVEF
who are already being treated with conventional
therapy (73–82). (Level of Evidence: B)
2005 recommendation remains
current in 2009 update.
Class III
outine combined use of an ACE inhibitor, ARB, and
aldosterone antagonist is not recommended for patients
with current or prior symptoms of HF and reduced LVEF.
(Level of Evidence: C)
1. Routine combined use of an ACE inhibitor, ARB, and
aldosterone antagonist is not recommended for
patients with current or prior symptoms of HF and
reduced LVEF. (Level of Evidence: C)
2005 recommendation remains
current in 2009 update.
alcium channel blocking drugs are not indicated as routine
treatment for HF in patients with current or prior
symptoms of HF and reduced LVEF. (Level of Evidence: A)
2. Calcium channel blocking drugs are not indicated as
routine treatment for HF in patients with current or
prior symptoms of HF and reduced LVEF (138–141).
(Level of Evidence: A)
2005 recommendation remains
current in 2009 update.
ong-term use of an infusion of a positive inotropic drug
may be harmful and is not recommended for patients
with current or prior symptoms of HF and reduced LVEF,
except as palliation for patients with end-stage disease
who cannot be stabilized with standard medical treatment
(see recommendations for Stage D). (Level of Evidence: C)
3. Long-term use of an infusion of a positive inotropic
drug may be harmful and is not recommended for
patients with current or prior symptoms of HF and
reduced LVEF, except as palliation for patients with
end-stage disease who cannot be stabilized with
standard medical treatment (see recommendations for
Stage D). (Level of Evidence: C)
2005 recommendation remains
current in 2009 update.
se of nutritional supplements as treatment for HF is not
indicated in patients with current or prior symptoms of HF
and reduced LVEF. (Level of Evidence: C)
4. Use of nutritional supplements as treatment for HF is
not indicated in patients with current or prior
symptoms of HF and reduced LVEF. (Level of
Evidence: C)
2005 recommendation remains
current in 2009 update.
ormonal therapies other than to replete deficiencies are
not recommended and may be harmful to patients with
current or prior symptoms of HF and reduced LVEF. (Level
of Evidence: C)
5. Hormonal therapies other than to replete deficiencies
are not recommended and may be harmful to patients
with current or prior symptoms of HF and reduced
LVEF. (Level of Evidence: C)
2005 recommendation remains
current in 2009 update.
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easures listed as Class I recommendations for patients in
tage A or B are also appropriate for patients with current or
rior symptoms of HF (also see Section 5, Treatment of
pecial Populations). In addition, moderate sodium restric-
ion, along with daily measurement of weight, is indicated
o permit effective use of lower and safer doses of diuretic
rugs, even if overt sodium retention can be controlled by
he use of diuretics. Immunization with influenza and
neumococcal vaccines may reduce the risk of a respiratory
nfection. Although most patients should not participate in
eavy labor or exhaustive sports, physical activity should be
ncouraged (except during periods of acute exacerbation of
he signs and symptoms of HF, or in patients with suspected
yocarditis), because restriction of activity promotes phys-
cal deconditioning, which may adversely affect clinical
tatus and contribute to the exercise intolerance of patients
ith HF (142–145).
Three classes of drugs can exacerbate the syndrome of HF
nd should be avoided in most patients:
. Antiarrhythmic agents (146) can exert important car-
diodepressant and proarrhythmic effects. Of available
agents, only amiodarone and dofetilide (147) have been
shown not to adversely affect survival.
. Calcium channel blockers can lead to worsening HF and
have been associated with an increased risk of cardiovas-
cular events (148). Of available calcium channel blockers,
only the vasoselective ones have been shown not to
adversely affect survival (139,149).
. Nonsteroidal anti-inflammatory drugs can cause sodium
retention and peripheral vasoconstriction and can atten-
uate the efficacy and enhance the toxicity of diuretics and
ACE inhibitors (84–87). A discussion of the use of
aspirin as a unique agent is found later in this section (see
Section 4.3.1.2.2.1., Angiotensin Converting Enzyme
Inhibitors in the Management of Heart Failure, in the
full-text guideline).
Patients with HF should be monitored carefully for
hanges in serum potassium, and every effort should be
ade to prevent the occurrence of either hypokalemia or
yperkalemia, both of which may adversely affect cardiac
xcitability and conduction and may lead to sudden death
150). Activation of both the sympathetic nervous system
nd renin-angiotensin system can lead to hypokalemia
151,152), and most drugs used for the treatment of HF can
lter serum potassium (153). Even modest decreases in
erum potassium can increase the risks of using digitalis and
ntiarrhythmic drugs (150,154), and even modest increases
n serum potassium may prevent the use of treatments
nown to prolong life (155). Hence, many experts believe
hat serum potassium concentrations should be targeted in
he 4.0 to 5.0 mmol per liter range. In some patients,
orrection of potassium deficits may require supplementa-
ion of magnesium and potassium (156). In others (partic-
larly those taking ACE inhibitors alone or in combination oith aldosterone antagonists), the routine prescription of po-
assium salts may be unnecessary and potentially deleterious.
Of the general measures that should be used in patients
ith HF, possibly the most effective yet least used is close
bservation and follow-up. Nonadherence with diet and
edications can rapidly and profoundly affect the clinical
tatus of patients, and increases in body weight and minor
hanges in symptoms commonly precede by several days the
ccurrence of major clinical episodes that require emergency
are or hospitalization. Patient education and close super-
ision, which includes surveillance by the patient and his or
er family, can reduce the likelihood of nonadherence and
ead to the detection of changes in body weight or clinical
tatus early enough to allow the patient or a healthcare
rovider an opportunity to institute treatments that can
revent clinical deterioration. Supervision need not be
erformed by a physician and may ideally be accomplished
y a nurse or physician’s assistant with special training in the
are of patients with HF. Such an approach has been
eported to have significant clinical benefits (157–160).
ecommendations Concerning Aldosterone Antagonists. The
ddition of low-dose aldosterone antagonists is recom-
ended in carefully selected patients with moderately severe
r severe HF symptoms and recent decompensation or with
V dysfunction early after MI. These recommendations are
ased on the strong data demonstrating reduced death and
ehospitalization in 2 clinical trial populations (155,161).
he entry criteria for these trials describe a broader popu-
ation than was actually enrolled, such that the favorable
fficacy/ toxicity ratio may not be as applicable to patients at
he margins of trial eligibility. For both of these major trials,
atients were excluded for a serum creatinine level in excess
f 2.5 mg per dL, but few patients were actually enrolled
ith serum creatinine levels over 1.5 mg per dL. In the trial
f patients after MI, there was a significant interaction
etween serum creatinine and benefit of eplerenone. The
verage serum creatinine of enrolled patients was 1.1 mg per
L, above which there was no demonstrable benefit for
urvival.
To minimize the risk of life-threatening hyperkalemia in
atients with low LVEF and symptoms of HF, patients
hould have initial serum creatinine less than 2.0 to 2.5 mg
er dL without recent worsening and serum potassium less
han 5.0 mEq per liter without a history of severe hyperka-
emia. In view of the consistency of evidence for patients
ith low LVEF early after MI and patients with recent
ecompensation and severe symptoms, it may be reasonable
o consider addition of aldosterone antagonists to loop
iuretics for some patients with mild to moderate symptoms
f HF; however, the writing committee strongly believes
hat there are insufficient data or experience to provide a
pecific or strong recommendation. Because the safety and
fficacy of aldosterone antagonist therapy have not been
hown in the absence of loop diuretic therapy, it is not
urrently recommended that such therapy be given without
ther concomitant diuretic therapy in chronic HF. Al-
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April 14, 2009:1343–82 2009 Guideline Focused Update on Heart Failurehough 17% of patients in the CHARM (Candesartan in
eart Failure: Assessment of Reduction in Mortality and
orbidity) add-on trial (83) were receiving spironolactone,
he safety of the combination of ACE inhibitors, ARBs,
nd aldosterone antagonists has not been explored ade-
uately, and this combination cannot be recommended.
.3.1.2.5. VENTRICULAR ARRHYTHMIAS AND PREVENTION OF SUDDEN DEATH.
atients with LV dilation and reduced LVEF frequently
anifest ventricular tachyarrhythmias, both nonsustained
entricular tachycardia (VT) and sustained VT. The cardiac
ortality of patients with all types of ventricular tachyar-
hythmias is high. The high mortality results from progres-
ive HF, as well as from sudden death. Sudden death is
ften equated with a primary arrhythmic event, but multiple
auses of sudden death have been documented and include
schemic events such as acute MI (162), electrolyte distur-
ances, pulmonary or systemic emboli, or other vascular
vents. Although ventricular tachyarrhythmias are the most
ommon rhythms associated with unexpected sudden death,
radycardia and other pulseless supraventricular rhythms are
ommon in patients with advanced HF (163).
Sudden death can be decreased meaningfully by the
herapies that decrease disease progression, as discussed
lsewhere in these guidelines. For instance, clinical trials
ith beta blockers have shown a reduction in sudden death,
s well as in all-cause mortality, in both postinfarction
atients and patients with HF regardless of cause
54,58,60,164,165). Aldosterone antagonists decrease sud-
en death and overall mortality in HF early after MI and in
dvanced HF (161). Sudden unexpected death can be
ecreased further by the use of implanted devices that
erminate sustained arrhythmias (40,102). Even when
pecific antiarrhythmic therapy is necessary to diminish
ecurrent ventricular tachyarrhythmias and device firings,
he frequency and tolerance of arrhythmias may be
mproved with appropriate therapy for HF. In some
ases, definitive therapy of myocardial ischemia or other
eversible factors may prevent recurrence of tachyarrhyth-
ia, particularly polymorphic VT, ventricular fibrillation,
nd nonsustained VT. Nonetheless, implantable defibril-
ators should be recommended in all patients who have
ad a life-threatening tachyarrhythmia and have an other-
ise good prognosis.
The absolute frequency of sudden death is highest in
atients with severe symptoms, or Stage D HF. Many
atients with end-stage symptoms experience “sudden
eath” that is nonetheless expected. Prevention of sudden
eath in this population could potentially shift the mode of
eath from sudden to that of progressive HF without
ecreasing total mortality, as competing risks of death
merge. On the other hand, prevention of sudden death in
ild HF may allow many years of meaningful survival. This
akes it imperative for physicians to not only assess an
ndividual patient’s risk for sudden death but also assess
verall prognosis and functional capacity before consider-
tion of device implantation. aecondary Prevention of Sudden Death. Patients with previous
ardiac arrest or documented sustained ventricular arrhyth-
ias have a high risk of recurrent events. Implantation of an
CD has been shown to reduce mortality in cardiac arrest
urvivors. An ICD is indicated for secondary prevention of
eath from ventricular tachyarrhythmias in patients with
therwise good clinical function and prognosis, for whom
rolongation of survival is a goal. Patients with chronic HF
nd a low EF who experience syncope of unclear origin have
high rate of subsequent sudden death and should also be
onsidered for placement of an ICD (95). However, when
entricular tachyarrhythmias occur in a patient with a
rogressive and irreversible downward spiral of clinical HF
ecompensation, placement of an ICD is not indicated to
revent recurrence of sudden death, because death is likely
mminent regardless of mode. An exception may exist for
he small minority of patients for whom definitive therapy
uch as cardiac transplantation is planned.
rimary Prevention of Sudden Death. Patients with low EF
ithout prior history of cardiac arrest, spontaneous VT, or
nducible VT (positive programmed electrical stimulation
tudy) have a risk of sudden death that is lower than for
hose who have experienced previous events, but it remains
ignificant. Within this group, it has not yet been possible to
dentify those patients at highest risk, especially in the
bsence of prior MI. Approximately 50% to 70% of patients
ith low EF and symptomatic HF have episodes of non-
ustained VT on routine ambulatory electrocardiographic
onitoring; however, it is not clear whether the occurrence
f complex ventricular arrhythmias in these patients with
F contributes to the high frequency of sudden death or,
lternatively, simply reflects the underlying disease process
166–168). Antiarrhythmic drugs to suppress premature
entricular depolarizations and nonsustained ventricular ar-
hythmias have not improved survival (88,89), although
onsustained VT may play a role in triggering ventricular
achyarrhythmias. Furthermore, most antiarrhythmic drugs
ave negative inotropic effects and can increase the risk of
erious arrhythmia; these adverse cardiovascular effects are
articularly pronounced in patients with low EF (90,146,
69). This risk is especially high with the use of class IA
gents (quinidine and procainamide), class IC agents (fle-
ainide and propafenone), and some class III agents (D-
otalol) (88,89,170,171), which have increased mortality in
ost-MI trials (172). Amiodarone is a class III antiarrhyth-
ic agent but differs from other drugs in this class in having
sympatholytic effect on the heart (173). Amiodarone has
een associated with overall neutral effects on survival when
dministered to patients with low EF and HF (93,174–
76). Amiodarone therapy may also act through mecha-
isms other than antiarrhythmic effects, because amioda-
one has been shown in some trials to increase LVEF and
ecrease the incidence of worsening HF (175,176). Side
ffects of amiodarone have included thyroid abnormalities,
ulmonary toxicity, hepatotoxicity, neuropathy, insomnia,
nd numerous other reactions. Therefore, amiodarone
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atients with HF, with or without frequent premature
entricular depolarizations or asymptomatic nonsustained
T; however, it remains the agent most likely to be safe and
ffective when antiarrhythmic therapy is necessary to pre-
ent recurrent atrial fibrillation or symptomatic ventricular
rrhythmias. Other pharmacological antiarrhythmic thera-
ies, apart from beta blockers, are rarely indicated in HF but
ay occasionally be used to suppress recurrent ICD shocks
hen amiodarone has been ineffective or discontinued
wing to toxicity.
The role of ICDs in the primary prevention of sudden death
n patients without prior history of symptomatic arrhythmias
as been explored recently in a number of trials. If sustained
entricular tachyarrhythmias can be induced in the electro-
hysiology laboratory in patients with previous MI or chronic
schemic heart disease, the risk of sudden death in these
atients is in the range of 5% to 6% per year and can be
mproved by ICD implantation (96).
The role of ICD implantation for the primary prevention
f sudden death in patients with HF and low EF and no
istory of spontaneous or inducible VT has been addressed
y several large trials that used only readily available clinical
ata as entry criteria (93,97,98). The first of these demon-
trated that ICDs, compared with standard medical therapy,
ecreased the occurrence of total mortality for patients with
F of 30% or less after remote MI (97). Absolute mortality
as decreased in the ICD arm by 5.6%, a relative decrease
f 31% over 20 months. In a second trial, a survival benefit
as not demonstrated with devices implanted within 6 to 40
ays after an acute MI in patients who at that time had an
F less than 35% and abnormal heart rate variability.
lthough sudden deaths were decreased, there was an
ncrease in other events, and ICD implantation did not
onfer any survival benefit in this setting (98). A third trial
xamining the benefit of ICD implantation for patients with
F less than 35% and NYHA functional class II to III
ymptoms of HF included both ischemic and nonischemic
auses of HF; absolute mortality was decreased by 7.2% over
5-year period in the arm that received a simple “shock-
ox” ICD with backup pacing at a rate of 40 bpm. This
epresented a relative mortality decrease of 23%, which was
survival increase of 11% (93). There was no improvement
n survival during the first year, with a 1.8% absolute survival
enefit per year averaged over the next 4 years. The
EFINITE (Defibrillators in Non-Ischemic Cardiomyop-
thy Treatment Evaluation) trial compared medical therapy
lone with medical therapy plus an ICD in patients with
onischemic cardiomyopathy, NYHA class I to III HF, and
n LVEF less than 36% (177). The ICD was associated
ith a reduction in all-cause mortality that did not reach
tatistical significance but was consistent in terms of mag-
itude of effect (30%) with the findings of the MADIT II
Multicenter Automatic Defibrillator Implantation II) (97)
nd the SCD-HeFT (Sudden Cardiac Death in Heart tailure: Trial of prophylactic amiodarone versus implant-
ble defibrillator therapy) (92).
There is an intrinsic variability in measurement of EF
articularly shortly after recovery from an acute coronary
yndrome event. Moreover, as reviewed earlier, the pivotal
rimary prevention trials used a variable inclusion EF,
anging below 30% or 36%. Given the totality of the data
emonstrating the efficacy of an ICD in reducing overall
ortality in a population with dilated cardiomyopathy of
ither ischemic or nonischemic origins, the current recom-
endation is to include all such patients with an LVEF of
ess than or equal to 35%.
ICDs are highly effective in preventing death due to
entricular tachyarrhythmias; however, frequent shocks
rom an ICD can lead to a reduced quality of life, whether
riggered appropriately by life-threatening rhythms or inap-
ropriately by sinus or other supraventricular tachycardia.
or symptoms from recurrent discharges triggered by ven-
ricular arrhythmias or atrial fibrillation, antiarrhythmic
herapy, most often amiodarone, may be added. For recur-
ent ICD discharges from VT despite antiarrhythmic ther-
py, catheter ablation may be effective (178).
It is important to recognize that ICDs have the potential
o aggravate HF and have been associated with an increase
n HF hospitalizations (97,99). This may result from right
entricular pacing that produces dyssynchronous cardiac
ontraction; however, the occurrence of excess nonsudden
vents with ICDs placed early after MI suggests that other
actors may also limit the overall benefit from ICDs. Careful
ttention to the details of ICD implantation, programming,
nd pacing function is important for all patients with low
F who are treated with an ICD. The ACC/AHA/HRS
008 Guidelines for Device-Based Therapy of Cardiac
hythm Abnormalities (40) provides further discussion of
he potential problem of worsening HF and LV function in
ll patients with right ventricular pacing.
The decision regarding the balance of potential risks and
enefits of ICD implantation for an individual patient thus
emains a complex one. A decrease in incidence of sudden
eath does not necessarily translate into decreased total
ortality, and decreased total mortality does not guarantee
prolongation of survival with meaningful quality of life.
his concept is particularly important in patients with
imited prognosis owing to advanced HF or other serious
omorbidities, because there was no survival benefit ob-
erved from ICD implantation until after the first year in 2
f the major trials (93,97). Furthermore, the average age of
atients with HF and low EF is over 70 years, a population
ot well represented in any of the ICD trials. Comorbidities
ommon in the elderly population, such as prior stroke,
hronic pulmonary disease, and crippling arthritic condi-
ions, as well as nursing home residence, should be factored
nto discussions regarding ICD. Atrial fibrillation, a com-
on trigger for inappropriate shocks, is more prevalent in
he elderly population. The gap between community and
rial populations is particularly important for a device
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April 14, 2009:1343–82 2009 Guideline Focused Update on Heart Failureherapy that may prolong survival but has no positive impact
n function or quality of life. Some patients may suffer a
iminished quality of life because of device-site complica-
ions, such as bleeding, hematoma, or infections, or after
CD discharges, particularly those that are inappropriate.
Consideration of ICD implantation is thus recom-
ended in patients with EF less than or equal to 35% and
ild to moderate symptoms of HF and in whom survival
ith good functional capacity is otherwise anticipated to
xtend beyond 1 year. Because medical therapy may sub-
tantially improve EF, consideration of ICD implants
hould follow documentation of sustained reduction of EF
espite a course of beta blockers and ACE inhibitors or
RBs; however, ICDs are not warranted in patients with
efractory symptoms of HF (Stage D) or in patients with
oncomitant diseases that would shorten their life expect-
ncy independent of HF. Before implantation, patients
hould be fully informed of their cardiac prognosis, includ-
ng the risk of both sudden and nonsudden mortality; the
fficacy, safety, and risks of an ICD; and the morbidity
ssociated with an ICD shock. Patients and families should
learly understand that the ICD does not improve clinical
unction or delay HF progression. Most important, the
ossible reasons and process for potential future deactivation
f defibrillator features should be discussed long before
unctional capacity or outlook for survival is severely
educed.
.3.1.3.3. HYDRALAZINE AND ISOSORBIDE DINITRATE. In a large-scale
rial that compared the vasodilator combination with pla-
ebo, the use of hydralazine and isosorbide dinitrate reduced
ortality but not hospitalizations in patients with HF
reated with digoxin and diuretics but not an ACE inhibitor
r beta blocker (136,137). However, in another large-scale
rial that compared the vasodilator combination with an
CE inhibitor, the ACE inhibitor produced more favorable
ffects on survival (52), a benefit not evident in the subgroup
f patients with Class III to IV HF. In both trials, the use
f hydralazine and isosorbide dinitrate produced frequent
dverse reactions (primarily headache and gastrointestinal
omplaints), and many patients could not continue treat-
ent at target doses.
Of note, a post hoc retrospective analysis of both vaso-
ilator trials demonstrated particular efficacy of isosorbide
initrate and hydralazine in the African American cohort
119). A confirmatory trial has been done. In that trial,
hich was limited to the patients self-described as African
merican, the addition of hydralazine and isosorbide dini-
rate to standard therapy with an ACE inhibitor and/or a
eta blocker was shown to be of significant benefit (120).
he benefit was presumed to be related to enhanced nitric
xide bioavailability. Accordingly, this combination is rec-
mmended for African Americans who remain symptom-
tic despite optimal medical therapy. Whether this benefit is
vident in other patients with HF remains to be investi-
ated. The combination of hydralazine and isosorbide
initrate should not be used for the treatment of HF in tatients who have no prior use of an ACE inhibitor and
hould not be substituted for ACE inhibitors in patients
ho are tolerating ACE inhibitors without difficulty.
Despite the lack of data with the vasodilator combination
n patients who are intolerant of ACE inhibitors, the
ombined use of hydralazine and isosorbide dinitrate may be
onsidered as a therapeutic option in such patients. How-
ver, compliance with this combination has generally been
oor because of the large number of tablets required and the
igh incidence of adverse reactions (52,136). For patients
ith more severe HF symptoms and ACE inhibitor intol-
rance, the combination of hydralazine and nitrates is used
requently, particularly when ACE inhibitor therapy is
imited by hypotension or renal insufficiency. There are,
owever, no trials addressing the use of isosorbide dinitrate
nd hydralazine specifically in the population of patients
ho have persistent symptoms and intolerance to inhibitors
f the renin-angiotensin system.
.3.1.3.4. CARDIAC RESYNCHRONIZATION THERAPY. Approximately
ne-third of patients with low EF and Class III to IV
ymptoms of HF manifest a QRS duration greater than 0.12
econds (179–181). This electrocardiographic representa-
ion of abnormal cardiac conduction has been used to
dentify patients with dyssynchronous ventricular contrac-
ion. While imperfect, no other consensus definition of
ardiac dyssynchrony exists as yet, although several echo-
ardiographic measures appear promising. The mechanical
onsequences of dyssynchrony include suboptimal ventric-
lar filling, a reduction in LV dP/dt (rate of rise of
entricular contractile force or pressure), prolonged duration
and therefore greater severity) of mitral regurgitation, and
aradoxical septal wall motion (182–184). Ventricular dys-
ynchrony has also been associated with increased mortality
n HF patients (103–105). Dyssynchronous contraction can
e addressed by electrically activating the right and left
entricles in a synchronized manner with a biventricular
acemaker device. This approach to HF therapy, commonly
alled cardiac resynchronization therapy (CRT), may en-
ance ventricular contraction and reduce the degree of
econdary mitral regurgitation (106–108). In addition, the
hort-term use of CRT has been associated with improve-
ents in cardiac function and hemodynamics without an
ccompanying increase in oxygen use (109), as well as adaptive
hanges in the biochemistry of the failing heart (107).
To date, more than 4000 HF patients with ventricular
yssynchrony have been evaluated in randomized controlled
rials of optimal medical therapy alone versus optimal
edical therapy plus CRT with or without an ICD. CRT,
hen added to optimal medical therapy in persistently
ymptomatic patients, has resulted in significant improve-
ents in quality of life, functional class, exercise capacity (by
eak oxygen uptake) and exercise distance during a
-minute walk test, and EF in patients randomized to CRT
110) or to the combination of CRT and ICD (102,111,
12). In a meta-analysis of several CRT trials, HF hospi-
alizations were reduced by 32% and all-cause mortality by
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ecame apparent after approximately 3 months of therapy
112). In 1 study, subjects were randomized to optimal
harmacological therapy alone, optimal medical therapy
lus CRT alone, or optimal medical therapy plus the
ombination of CRT and an ICD. Compared with optimal
edical therapy alone, both device arms significantly de-
reased the combined risk of all-cause hospitalization and
ll-cause mortality by approximately 20%, whereas the
ombination of a CRT and an ICD decreased all-cause
ortality significantly by 36% (113). More recently, in a
andomized controlled trial comparing optimal medical
herapy alone with optimal medical therapy plus CRT alone
without a defibrillator), CRT significantly reduced the
ombined risk of death of any cause or unplanned hospital
dmission for a major cardiovascular event (analyzed as time
o first event) by 37% (101). In that trial, all-cause mortality
as significantly reduced by 36% and HF hospitalizations
y 52% with the addition of CRT.
Thus, there is strong evidence to support the use of CRT
o improve symptoms, exercise capacity, quality of life,
VEF, and survival and to decrease hospitalizations in
atients with persistently symptomatic HF undergoing
ptimal medical therapy who have cardiac dyssynchrony (as
videnced by a prolonged QRS duration). The use of an
CD in combination with CRT should be based on the
ndications for ICD therapy.
With few exceptions, resynchronization trials have en-
olled patients in normal sinus rhythm. Although the entry
riteria specified QRS duration only longer than 0.12
econds, the average QRS duration in the large trials was
onger than 0.15 seconds, with less information demonstrat-
ng benefit in patients with lesser prolongation of QRS.
wo small studies, one randomized (114) and the other
bservational (115), evaluated the potential benefit of CRT
n HF patients with ventricular dyssynchrony and atrial
brillation. Although both studies demonstrated the benefit
f CRT in these patients, the total number of patients
xamined (fewer than 100) precludes a recommendation for
RT in otherwise eligible patients with atrial fibrillation.
o date, only a small number of patients with “pure” right
undle-branch block have been enrolled in CRT trials.
imilarly, the prolonged QRS duration associated with right
entricular pacing has also been associated with ventricular
yssynchrony that may be improved by CRT, but no
ublished studies have addressed this situation as yet.
ecommendations regarding CRT for patients with LVEF
f less than or equal to 35%, NYHA functional class III, and
mbulatory class IV symptoms or dependence on ventricular
acing have been updated to be consistent with the ACC/
HA/HRS 2008 Guidelines for Device-Based Therapy of
ardiac Rhythm Abnormalities (40).
Ten studies have reported on CRT peri-implant morbid-
ty and mortality. There were 13 deaths in 3113 patients
0.4%). From a pooled assessment of 3475 patients in 17
tudies, the success rate of implantation was approximately m0% (112). Device-related problems during the first 6
onths after implantation reported in 13 studies included
ead malfunction or dislodgement in 8.5%, pacemaker
roblems in 6.7%, and infection in 1.4% of cases. These
orbidity and mortality data are derived from trials that
sed expert centers. Results in individual clinical centers
ay vary considerably and are subject to a significant
earning curve for each center; however, as implantation
echniques evolve and equipment improves, complication
ates may also decline (112).
.3.1.5.2. INTERMITTENT INTRAVENOUS POSITIVE INOTROPIC THERAPY.
lthough positive inotropic agents can improve cardiac
erformance during short- and long-term therapy
185,186), long-term oral therapy with these drugs has not
mproved symptoms or clinical status (131,187–197) and
as been associated with a significant increase in mortality,
specially in patients with advanced HF (195,198–203).
espite these data, some physicians have proposed that the
egularly scheduled intermittent use of intravenous positive
notropic drugs (e.g., dobutamine or milrinone) in a super-
ised outpatient setting might be associated with some
linical benefits (204–206).
However, there has been little experience with intermit-
ent home infusions of positive inotropic agents in con-
rolled clinical trials. Nearly all of the available data are
erived from open-label and uncontrolled studies or from
rials that have compared one inotropic agent with another,
ithout a placebo group (204–207). Most trials have been
mall and short in duration and thus have not been able to
rovide reliable information about the effect of treatment on
he risk of serious cardiac events. Much, if not all, of the
enefit seen in these uncontrolled reports may have been
elated to the increased surveillance of the patient’s status
nd intensification of concomitant therapy and not to the
se of positive inotropic agents. Only 1 placebo-controlled
rial of intermittent intravenous positive inotropic therapy
as been published (208), and its findings are consistent
ith the results of long-term studies with continuous oral
ositive inotropic therapy in HF (e.g., with milrinone),
hich showed little efficacy and were terminated early
ecause of an increased risk of death.
Given the lack of evidence to support their efficacy and
oncerns about their toxicity, intermittent infusions of
ositive inotropic agents (whether at home, in an outpatient
linic, or in a short-stay unit) should not be used in the
ong-term treatment of HF, even in its advanced stages.
he use of continuous infusions of positive inotropic agents
s palliative therapy in patients with end-stage disease
Stage D) is discussed later in this document (123,124).
.4. Patients With Refractory End-Stage
eart Failure (Stage D)
he role of intermittent infusions as effective treatment for
dvanced HF has been further clarified by an additional
ulticenter trial (Table 4).
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April 14, 2009:1343–82 2009 Guideline Focused Update on Heart FailureMost patients with HF due to reduced LVEF respond
avorably to pharmacological and nonpharmacological treat-
ents and enjoy a good quality of life and enhanced
urvival; however, some patients do not improve or experi-
nce rapid recurrence of symptoms despite optimal medical
herapy. Such patients characteristically have symptoms at
est or on minimal exertion, including profound fatigue;
annot perform most activities of daily living; frequently
ave evidence of cardiac cachexia; and typically require
epeated and/or prolonged hospitalizations for intensive
able 4. Updates to Section 4.4. Patients With Refractory End
2005 Guideline Recommendations 2009 F
Updates to Section 4.4. Patients With R
C
eticulous identification and control of fluid retention is
recommended in patients with refractory end-stage
HF. (Level of Evidence: B)
1. Meticulous id
recommende
(209–216). (
eferral for cardiac transplantation in potentially
eligible patients is recommended for patients with
refractory end-stage HF. (Level of Evidence: B)
2. Referral for
patients is re
end-stage HF
eferral of patients with refractory end-stage HF to an
HF program with expertise in the management of
refractory HF is useful. (Level of Evidence: A)
3. Referral of p
program wit
HF is useful
ptions for end-of-life care should be discussed with the
patient and family when severe symptoms in patients
with refractory end-stage HF persist despite
application of all recommended therapies. (Level of
Evidence: C)
4. Options for e
patient and
with refracto
of all recomm
atients with refractory end-stage HF and
implantable defibrillators should receive
information about the option to inactivate
defibrillation. (Level of Evidence: C)
5. Patients with
defibrillators
inactivate the
Cl
onsideration of an LV assist device as permanent or
“destination” therapy is reasonable in highly selected
patients with refractory end-stage HF and an
estimated 1-year mortality over 50% with medical
therapy. (Level of Evidence: B)
1. Consideratio
“destination”
patients with
1-year morta
(222,223). (
Cl
ulmonary artery catheter placement may be
reasonable to guide therapy in patients with
refractory end-stage HF and persistently severe
symptoms. (Level of Evidence: C)
1. Pulmonary a
reasonable t
end-stage HF
(217,224). (
he effectiveness of mitral valve repair or replacement
is not established for severe secondary mitral
regurgitation in refractory end-stage HF. (Level of
Evidence: C)
2. The effective
is not well es
regurgitation
(Level of Evid
ontinuous intravenous infusion of a positive inotropic
agent may be considered for palliation of symptoms
in patients with refractory end-stage HF. (Level of
Evidence: C)
3. Continuous i
agent may b
patients with
of Evidence:
C
artial left ventriculectomy is not recommended in
patients with nonischemic cardiomyopathy and
refractory end-stage HF. (Level of Evidence: C)
1. Partial left v
patients with
refractory en
outine intermittent infusions of positive inotropic
agents are not recommended for patients with
refractory end-stage HF. (Level of Evidence: B)
2. Routine inte
inotropic age
refractory enanagement. These individuals represent the most ad- Sanced stage of HF and should be considered for specialized
reatment strategies, such as mechanical circulatory support,
ontinuous intravenous positive inotropic therapy, referral
or cardiac transplantation, or hospice care. Before a patient
s considered to have refractory HF, physicians should
onfirm the accuracy of the diagnosis, identify any contrib-
ting conditions, and ensure that all conventional medical
trategies have been optimally employed. Measures listed as
lass I recommendations for patients in stages A, B, and C
re also appropriate for patients in end-stage HF (also see
e Heart Failure (Stage D)
d Update Recommendations Comments
tory End-Stage Heart Failure (Stage D)
cation and control of fluid retention is
atients with refractory end-stage HF
of Evidence: B)
2005 recommendation remains
current in 2009 update.
c transplantation in potentially eligible
ended for patients with refractory
). (Level of Evidence: B)
2005 recommendation remains
current in 2009 update.
s with refractory end-stage HF to a HF
rtise in the management of refractory
221). (Level of Evidence: A)
2005 recommendation remains
current in 2009 update.
life care should be discussed with the
when severe symptoms in patients
-stage HF persist despite application
d therapies. (Level of Evidence: C)
2005 recommendation remains
current in 2009 update.
tory end-stage HF and implantable
receive information about the option to
rillator. (Level of Evidence: C)
2005 recommendation remains
current in 2009 update.
a
n LV assist device as permanent or
py is reasonable in highly selected
ctory end-stage HF and an estimated
er 50% with medical therapy
f Evidence: B)
2005 recommendation remains
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persistently severe symptoms
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rognosis and options for end-of-life care should be initi-
ted (see Section 7, End-of-Life Considerations, in the
ull-text guideline) (2).
.4.3. Intravenous Peripheral Vasodilators and
ositive Inotropic Agents
atients with refractory HF are hospitalized frequently for
linical deterioration, and during such admissions, they com-
only receive infusions of both positive inotropic agents
dobutamine, dopamine, or milrinone) and vasodilator drugs
nitroglycerin, nitroprusside, or nesiritide) in an effort to
mprove cardiac performance, facilitate diuresis, and promote
linical stability. Some physicians have advocated the place-
ent of pulmonary artery catheters in patients with refractory
F, with the goal of obtaining hemodynamic measurements
hat might be used to guide the selection and titration of
herapeutic agents (224). However, the logic of this approach
as been questioned, because many useful drugs for HF
roduce benefits by mechanisms that cannot be evaluated by
easuring their short-term hemodynamic effects (232,233).
egardless of whether invasive hemodynamic monitoring is
sed, once the clinical status of the patient has stabilized, every
ffort should be made to devise an oral regimen that can
aintain symptomatic improvement and reduce the subse-
uent risk of deterioration. Assessment of the adequacy and
olerability of orally based strategies may necessitate observa-
ion in the hospital for at least 48 hours after the infusions arePatients who cannot be weaned from intravenous to
ral therapy despite repeated attempts may require place-
ent of an indwelling intravenous catheter to allow for
he continuous infusion of dobutamine or milrinone or,
s has been used more recently, nesiritide. Such a strategy
s commonly used in patients who are awaiting cardiac
ransplantation, but it may also be used in the outpatient
etting in patients who otherwise cannot be discharged
rom the hospital. The decision to continue intravenous
nfusions at home should not be made until all alternative
ttempts to achieve stability have failed repeatedly, be-
ause such an approach can present a major burden to the
amily and health services and may ultimately increase the
isk of death. However, continuous intravenous support
ay provide palliation of symptoms as part of an overall
lan to allow the patient to die with comfort at home
228,229). The use of continuous intravenous support to
llow hospital discharge should be distinguished from the
ntermittent administration of infusions of such agents to
atients who have been successfully weaned from inotro-
ic support (220). Intermittent outpatient infusions of
ither vasoactive drugs such as nesiritide or positive
notropic drugs have not shown to improve symptoms or
urvival in patients with advanced HF (220,230,231).
.5. The Hospitalized Patient (New)
ew recommendations and text have been developed on the
iscontinued (234). hospitalized patient (Table 5).
able 5. Recommendations for the Hospitalized Patient
2009 Focused Update Recommendations Comments
Class I
1. The diagnosis of HF is primarily based on signs and symptoms derived from a thorough history and physical examination. Clinicians
should determine the following:
New recommendation
a. adequacy of systemic perfusion;
b. volume status;
c. the contribution of precipitating factors and/or comorbidities;
d. if the heart failure is new onset or an exacerbation of chronic disease; and
e. whether it is associated with preserved ejection fraction.
Chest radiographs, electrocardiogram, and echocardiography are key tests in this assessment. (Level of Evidence: C)
2. Concentrations of B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) should be measured in
patients being evaluated for dyspnea in which the contribution of HF is not known. Final diagnosis requires interpreting these
results in the context of all available clinical data and ought not to be considered a stand alone test (235,236). (Level of Evidence: A)
New recommendation
3. Acute coronary syndrome precipitating HF hospitalization should be promptly identified by electrocardiogram and cardiac troponin
testing, and treated, as appropriate to the overall condition and prognosis of the patient. (Level of Evidence: C)
New recommendation
4. It is recommended that the following common potential precipitating factors for acute HF be identified as recognition of these
comorbidities is critical to guide therapy:
New recommendation
● acute coronary syndromes/coronary ischemia;
● severe hypertension;
● atrial and ventricular arrhythmias;
● infections;
● pulmonary emboli;
● renal failure; and
● medical or dietary noncompliance. (Level of Evidence: C)
5. Oxygen therapy should be administered to relieve symptoms related to hypoxemia. (Level of Evidence: C) New recommendation
T1
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1
1
1
1
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April 14, 2009:1343–82 2009 Guideline Focused Update on Heart Failureable 5. Continued
2009 Focused Update Recommendations Comments
Class I (Continued)
6. Whether the diagnosis of HF is new or chronic, patients who present with rapid decompensation and hypoperfusion associated with
decreasing urine output and other manifestations of shock are critically ill and rapid intervention should be used to improve
systemic perfusion. (Level of Evidence: C)
New recommendation
7. Patients admitted with HF and with evidence of significant fluid overload should be treated with intravenous loop diuretics. Therapy
should begin in the emergency department or outpatient clinic without delay, as early intervention may be associated with better
outcomes for patients hospitalized with decompensated HF (21,237,238). (Level of Evidence: B) If patients are already receiving
loop diuretic therapy, the initial intravenous dose should equal or exceed their chronic oral daily dose. Urine output and signs and
symptoms of congestion should be serially assessed, and diuretic dose should be titrated accordingly to relieve symptoms and to
reduce extracellular fluid volume excess. (Level of Evidence: C)
New recommendation
8. Effect of HF treatment should be monitored with careful measurement of fluid intake and output; vital signs; body weight,
determined at the same time each day; clinical signs (supine and standing) and symptoms of systemic perfusion and congestion.
Daily serum electrolytes, urea nitrogen, and creatinine concentrations should be measured during the use of IV diuretics or active
titration of HF medications. (Level of Evidence: C)
New recommendation
9. When diuresis is inadequate to relieve congestion, as evidenced by clinical evaluation, the diuretic regimen should be intensified
using either:
New recommendation
a. higher doses of loop diuretics;
b. addition of a second diuretic (such as metolazone, spironolactone or intravenous chlorothiazide); or
c. continuous infusion of a loop diuretic. (Level of Evidence: C)
0. In patients with clinical evidence of hypotension associated with hypoperfusion and obvious evidence of elevated cardiac filling
pressures (e.g., elevated jugular venous pressure; elevated pulmonary artery wedge pressure), intravenous inotropic or vasopressor
drugs should be administered to maintain systemic perfusion and preserve end-organ performance while more definitive therapy is
considered. (Level of Evidence: C)
New recommendation
1. Invasive hemodynamic monitoring should be performed to guide therapy in patients who are in respiratory distress or with clinical
evidence of impaired perfusion in whom the adequacy or excess of intracardiac filling pressures cannot be determined from
clinical assessment. (Level of Evidence: C)
New recommendation
2. Medications should be reconciled in every patient and adjusted as appropriate on admission to and discharge from the hospital.
(Level of Evidence: C)
New recommendation
3. In patients with reduced ejection fraction experiencing a symptomatic exacerbation of HF requiring hospitalization during chronic
maintenance treatment with oral therapies known to improve outcomes, particularly ACE inhibitors or ARBs and beta-blocker
therapy, it is recommended that these therapies be continued in most patients in the absence of hemodynamic instability or
contraindications. (Level of Evidence: C)
New recommendation
4. In patients hospitalized with HF with reduced ejection fraction not treated with oral therapies known to improve outcomes,
particularly ACE inhibitors or ARBs and beta-blocker therapy, initiation of these therapies is recommended in stable patients prior
to hospital discharge (239,240). (Level of Evidence: B)
New recommendation
5. Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of
intravenous diuretics, vasodilators, and inotropic agents. Beta-blocker therapy should be initiated at a low dose and only in stable
patients. Particular caution should be used when initiating beta blockers in patients who have required inotropes during their
hospital course (239,240). (Level of Evidence: B)
New recommendation
6. In all patients hospitalized with HF, both with preserved (see Section 4.3.2., Patients With HF and Normal LVEF, in the full-text
guideline) and low EF, transition should be made from intravenous to oral diuretic therapy with careful attention to oral diuretic
dosing and monitoring of electrolytes. With all medication changes, the patient should be monitored for supine and upright
hypotension, worsening renal function and HF signs/symptoms. (Level of Evidence: C)
New recommendation
7. Comprehensive written discharge instructions for all patients with a hospitalization for HF and their caregivers is strongly
recommended, with special emphasis on the following 6 aspects of care: diet, discharge medications, with a special focus on
adherence, persistence, and uptitration to recommended doses of ACE inhibitor/ARB and beta-blocker medication, activity level,
follow-up appointments, daily weight monitoring, and what to do if HF symptoms worsen. (Level of Evidence: C)
New recommendation
8. Postdischarge systems of care, if available, should be used to facilitate the transition to effective outpatient care for patients
hospitalized with HF (112,241–247). (Level of Evidence: B)
New recommendation
Class IIa
1. When patients present with acute HF and known or suspected acute myocardial ischemia due to occlusive coronary disease,
especially when there are signs and symptoms of inadequate systemic perfusion, urgent cardiac catheterization and
revascularization is reasonable where it is likely to prolong meaningful survival. (Level of Evidence: C)
New recommendation
2. In patients with evidence of severely symptomatic fluid overload in the absence of systemic hypotension, vasodilators such as
intravenous nitroglycerin, nitroprusside or nesiritide can be beneficial when added to diuretics and/or in those who do not respond
to diuretics alone. (Level of Evidence: C)
New recommendation
3. Invasive hemodynamic monitoring can be useful for carefully selected patients with acute HF who have persistent symptoms
despite empiric adjustment of standard therapies, and
New recommendation
a. whose fluid status, perfusion, or systemic or pulmonary vascular resistances are uncertain.
b. whose systolic pressure remains low, or is associated with symptoms, despite initial therapy,
c. whose renal function is worsening with therapy
d. who require parenteral vasoactive agents or
e. who may need consideration for advanced device therapy or transplantation. (Level of Evidence: C)
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2009 Guideline Focused Update on Heart Failure April 14, 2009:1343–82A patient may develop acute or progressive symptoms of
F and require hospitalization. In general, there are 3
linical profiles that describe the hospitalized patient with
F: 1) the patient with volume overload, manifested by
ulmonary and/or systemic congestion, frequently precipi-
ated by an acute increase in chronic hypertension; 2) the
atient with profound depression of cardiac output mani-
ested by hypotension, renal insufficiency, and/or a shock
yndrome, and 3) the patient with signs and symptoms of
oth fluid overload and shock. Irrespective of the presenting
linical picture, there have been a confusing variety of terms
n the literature used to describe these patients, including
cute HF syndrome, acute decompensated HF, or cardio-
enic shock. However different these 3 groups of patients
ay be in outcome, they can all be characterized as having
change in HF signs and symptoms resulting in a need for
rgent therapy. Patients with HF and preserved LVEF (see
ection 4.3.2, Patients With Heart Failure and Normal Left
entricular Ejection Fraction in the full-text guideline) are just
s likely to be admitted to hospital as those with HF and low
VEF (251). Admission with HF is often triggered by a
oncomitant cardiovascular event such as a symptomatic tachy-
rrhythmia, unstable coronary syndrome, or a cerebrovascular
vent; often the admission is related to medical or dietary
oncompliance. The threshold for admission may also be
owered when HF exacerbation is accompanied with a non-
ardiac condition such as pneumonia or newly diagnosed
nemia. Indeed, it is important to note that concurrent con-
itions and comorbidities such as coronary artery disease,
ypertension, valvular heart disease, arrhythmias, renal dys-
unction, diabetes, thromboembolism, and anemia are often
resent, more so than has usually been described in clinical
rials, and may precipitate or contribute to the pathophysiology
f the syndrome. Unfortunately, the precipitating event leading
o hospitalization is not always readily apparent.
ommon Factors That Precipitate Hospitalization for
eart Failure
Noncompliance with medical regimen, sodium and/or
fluid restriction
Acute myocardial ischemia
able 5. Continued
2009 Focused Update Recomme
Class IIa
4. Ultrafiltration is reasonable for patients with refractory congestion not respo
Cl
1. Intravenous inotropic drugs such as dopamine, dobutamine or milrinone mi
documented severe systolic dysfunction, low blood pressure and evidence o
maintain systemic perfusion and preserve end-organ performance. (Level of
C
1. Use of parenteral inotropes in normotensive patients with acute decompens
is not recommended (249). (Level of Evidence: B)
2. Routine use of invasive hemodynamic monitoring in normotensive patients
symptomatic response to diuretics and vasodilators is not recommended (2Uncorrected high blood pressure wAtrial fibrillation and other arrhythmias
Recent addition of negative inotropic drugs (e.g., vera-
pamil, nifedipine, diltiazem, beta blockers)
Pulmonary embolus
Nonsteroidal anti-inflammatory drugs
Excessive alcohol or illicit drug use
Endocrine abnormalities (e.g., diabetes mellitus, hyper-
thyroidism, hypothyroidism)
Concurrent infections (e.g., pneumonia, viral illnesses)
HF hospitalizations account for a substantial portion of
he overall costs of caring for patients with HF and may be
ssociated with a staggering degree of morbidity and mor-
ality, particularly in the elderly population. It is evident that
he prognosis after an index hospitalization for HF is
minous, with a 50% rate of readmission at 6 months and a
5% to 35% incidence of death at 12 months (252–256).
ndeed, many HF trials now incorporate the need for
ospitalization as an important endpoint with which to
valuate a new therapy; government agencies and insurance
ompanies are increasingly interested in understanding the
requency of repeat HF hospitalizations. Thus, it is impor-
ant to outline what should occur in the hospital for the HF
atient requiring therapy. The scope of these recommenda-
ions are based on evidence from the few available random-
zed trials evaluating management strategies in the acute
ecompensated HF patient (248–250,257,258), analyses of
arge registries, and consensus opinion. Additional and
ore comprehensive information on this subject may be
ound in the guidelines from the Heart Failure Society of
merica and the European Society of Cardiology
259,260,260a).
.5.1. Diagnostic Strategies
he diagnosis of HF in the hospitalized patient should be
ased primarily on signs and symptoms, as discussed in
ection 3.1., Initial Evaluation of Patients. Clinicians need
o determine as accurately and as quickly as possible 1) the
olume status of the patient, 2) the adequacy of circulatory
upport or perfusion, and 3) the role or presence of
recipitating factors and/or comorbidities. In the patient
ons Comments
tinued)
to medical therapy (248). (Level of Evidence: B) New recommendation
b
reasonable for those patients presenting with
cardiac output, with or without congestion, to
nce: C)
New recommendation
I
HF without evidence of decreased organ perfusion New recommendation
cute decompensated HF and congestion with
evel of Evidence: B)
New recommendationndati
(Con
nding
ass II
ght be
f low
Evide
lass II
ated
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April 14, 2009:1343–82 2009 Guideline Focused Update on Heart Failureirected toward understanding what has caused the appar-
nt acute worsening of clinical symptoms. Many of the steps
n this investigation are identical to those used in the initial
valuation of HF (see Sections 3.1.3., Evaluation of the
ause of Heart Failure and 3.2., Ongoing Evaluation of
atients, in the full-text guideline). When the diagnosis of
F is uncertain, determination of plasma BNP or NT-
roBNP concentration should be considered in patients
eing evaluated for dyspnea who have signs and symptoms
ompatible with HF. The natriuretic peptide concentration
hould not be interpreted in isolation but in the context of
ll available clinical data bearing on the diagnosis of HF.
An important cause of worsening HF, and for new-onset
F, is an acute MI. Because many patients admitted with
cute HF have coronary artery disease, troponins are typi-
ally evaluated at admission for acute exacerbation. Actual
riteria for an acute coronary event that may indicate the
eed for further intervention may be present in up to 20% of
atients (261,262). However, many other patients may have
ow levels of detectable troponins not meeting criteria for an
cute ischemic event but typical of chronic HF with an acute
xacerbation (263). Registry data have suggested that the
se of coronary angiography is low for patients hospitalized
ith decompensated HF and opportunities to diagnose
mportant coronary artery disease may be missed. Symptoms
f HF or cardiogenic shock associated with an ischemic
vent are covered in other guidelines (264,265) and are
eyond the scope of this update. For the patient with newly
iscovered HF, clinicians should be aware of the important
ole of coronary artery disease in causing HF and should be
ertain that coronary structure and function are well delin-
ated (see Section 3.1.2., Identification of a Structural and
unctional Abnormality) while simultaneously beginning
reatment. Coronary visualization may be an important part
f the evaluation of patients hospitalized with HF.
Often, patients with chronic HF are admitted with acute
ecompensation from a number of possible precipitating
auses. Clinicians should carefully review the patient’s
aintenance HF medications and decide whether adjust-
ents should be made as a result of the hospitalization. The
arge majority of patients with HF admitted to the hospital,
specially those with concomitant hypertension, should have
heir oral therapy continued, or even uptitrated, during
ospitalization. It is important to note that it has been
hown that continuation of beta blockers for most patients
s well tolerated and results in better outcomes (239,240).
ithholding of or reduction in beta-blocker therapy should
e considered only in patients hospitalized after recent
nitiation or increase in beta-blocker therapy or with marked
olume overload. Patients admitted with worsening
zotemia should be considered for a reduction in or tempo-
ary discontinuation of their ACE inhibitors, ARBs, and/or
ldosterone antagonists until renal function improves. Pa-
ients with marked volume overload will require intravenous
iuretic therapy with uptitration of diuretic dose and/or
ddition of synergistic diuretic agents. It should be noted rhat uptitration of ACE inhibitors or beta blockers during
ecompensation may reduce the efficacy of the acute inter-
entions to relieve congestion. Although it is important to
nsure that evidence-based medications are instituted prior
o the patient leaving the hospital, it is equally as critical to
eassess medications on admission and to adjust their
dministration in light of the worsening HF.
.5.2. Treatment in the Hospital
.5.2.1. DIURETICS: THE PATIENT WITH VOLUME OVERLOAD
atients admitted with evidence of significant fluid overload
hould initially be treated with loop diuretics, usually given
ntravenously. Therapy for this compelling presentation of
F should begin in the emergency department and should
e initiated without delay. Early intervention has been
ssociated with better outcomes for patients hospitalized
ith decompensated HF (266,267). After admission to the
ospital, patients should be carefully monitored in accor-
ance with the severity of their symptoms and the results of
nitial findings on the physical examination and laboratory
ssessment. Careful and frequent serial evaluation of the
atient is important primarily to assess volume status (see
ection 3.2.2., Assessment of Volume Status, in the full-text
uideline,) and adequacy of circulatory support. Laboratory
arameters are likewise necessary to judge efficacy of treat-
ent (see Sections 3.1.3.2., Laboratory Testing, and 3.2.3.,
aboratory Assessment). Monitoring of daily weight, su-
ine and standing vital signs, fluid input, and output is a
ecessary part of daily management; assessment of daily
lectrolytes and renal function should be done while intra-
enous diuretics or active HF medication titration is being
ndertaken.
Intravenous loop diuretics have the potential to reduce
lomerular filtration rate (GFR), further worsen neurohu-
oral activation, and produce electrolyte disturbances.
hus, although the use of diuretics may result in the
ffective relief of symptoms, their impact on mortality has
ot been well studied. Diuretics should be administered at
oses sufficient to produce a rate of diuresis that will
ptimize volume status and relieve signs and symptoms of
ongestion without inducing an excessively rapid reduction
n intravascular volume, which could result in hypotension,
enal dysfunction, or both (see Sections 4.3.1.2.1., Diuret-
cs, and 4.4.1., Management of Fluid Status, in the full-text
uideline). Because loop diuretics have a relatively short
alf-life, sodium reabsorption in the tubules will occur once
he tubular concentration of the diuretics declines. There-
ore, strictly limiting sodium intake and dosing the diuretic
ultiple times per day will enhance effectiveness of the
iuresis (209,268–274). Some patients may present with
ongestion and moderate to severe renal dysfunction. The
esponse to diuretics may be significantly blunted, requiring
igher initial doses. In many cases, reduction of fluid
verload may improve not only congestion but also renal
ysfunction, particularly if significant venous congestion is
educed (275).
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2009 Guideline Focused Update on Heart Failure April 14, 2009:1343–82Clinical experience suggests it is difficult to determine
hether congestion has been adequately treated in many
atients, and registry data have confirmed that patients are
requently discharged after a net weight loss of only a few
ounds. Although patients may rapidly improve symptom-
tically, they may remain hemodynamically compromised.
nfortunately, the routine use of serial natriuretic peptide
easurement (BNP or NT-proBNP) or even a Swan-Ganz
atheter to monitor hemodynamics has not been shown to
e helpful in improving the outcomes of the hospitalized
atient with HF. Nevertheless, careful evaluation of all
hysical findings, laboratory parameters, weight change, and
et fluid change should be considered before discharge
lanning is commenced.
When a patient with congestion fails to respond to initial
oses of intravenous diuretics, several options may be
onsidered. Efforts should be taken to make certain that,
ndeed, congestion persists and that another hemodynamic
rofile or perhaps another disease process is not evident.
his is particularly important for the patient with progres-
ive renal insufficiency. If there is substantial doubt about
he fluid status of the patient, HF experts suggest that it is
n appropriate time for a formal hemodynamic assessment
f ventricular filling pressures and cardiac output, typically
one with a right heart catheterization. If volume overload
s confirmed, the dose of the loop diuretic should be initially
ncreased to ensure that adequate drug levels reach the
idney. If this is inadequate, a second type of diuretic,
ypically a thiazide (metolazone or intravenous chlorothia-
ide) or spironolactone, can be added to improve diuretic
esponsiveness. As a third strategy, continuous infusion of
he loop diuretic may be considered. By continuous delivery
f the diuretic to the nephron, rebound resorption occurring
uring the time blood levels of diuretic are low is avoided
nd ototoxicity risk may actually be reduced (see Sections
.3.1.2.1., Diuretics, and 4.4.1., Management of Fluid
tatus) (209,210,274,276–282). If all diuretic strategies are
nsuccessful, ultrafiltration or another renal replacement
trategy may be reasonable. Ultrafiltration moves water and
mall to medium-weight solutes across a semipermeable
embrane to reduce volume overload. Because the electro-
yte concentration is similar to plasma, relatively more
odium can be removed than by diuretics (213,248,283–
85). Consultation with a kidney specialist may be appro-
riate before opting for any mechanical strategy to affect
iuresis.
.5.2.2. VASODILATORS
here are a number of clinical scenarios whereby the
ddition of vasodilators to the HF regimen of the hospital-
zed patient might be appropriate. For patients with ade-
uate blood pressure and ongoing congestion not sufficiently
esponsive to diuretics and standard oral therapy (e.g.,
aintenance of prior HF medications, if applicable), intra-
enous vasodilators such as nitroprusside, nitroglycerin, or
esiritide may be added to the treatment regimen. Regard- ress of the agent used, the clinician should make certain that
ntravascular volume is, in fact, expanded and that the
atient’s blood pressure can tolerate the addition of the
asodilating drug.
Intravenous nitroglycerin, primarily through venodilation
ffects, lowers preload and may help to more rapidly reduce
ulmonary congestion. Patients with HF and hypertension,
oronary ischemia, or significant mitral regurgitation are
ften cited as ideal candidates for the use of intravenous
itroglycerin. However, tachyphylaxis to nitroglycerin may
evelop rather quickly and up to 20% of those with HF may
evelop resistance to even high doses (286–288). Sodium
itroprusside is a balanced preload-reducing venodilator and
fterload-reducing arteriodilator that also dilates the pulmo-
ary vasculature. Data demonstrating efficacy are limited,
nd invasive hemodynamic blood pressure monitoring is
ypically required. Nitroprusside has the potential for pro-
ucing marked hypotension and is usually used in the
ntensive care setting as well; longer infusions of the drug
ave been associated with thiocyanate toxicity, particularly
n the setting of renal insufficiency. Nitroprusside is poten-
ially of value in severely congested patients with hyperten-
ion or severe mitral valve regurgitation complicating LV
ysfunction. Nesiritide (human BNP) reduces LV filling
ressure but has variable effects on cardiac output, urinary
utput, and sodium excretion. The severity of dyspnea is
educed more rapidly compared to diuretics alone. Because
esiritide has a longer effective half-life than nitroglycerin or
itroprusside, side effects such as hypotension may persist
onger. Conservative dosing of the drug (i.e., no bolus) and
se of only the recommended doses may reduce complica-
ions. Adverse renal consequences with nesiritide have been
uggested; careful monitoring of renal function is mandatory
257,289–294). The effects of nesiritide on mortality remain
ncertain and active clinical investigation is ongoing.
The role of intravenous vasodilators for the patient
ospitalized with HF cannot be generalized. The goals of
F therapy with vasodilators, in the absence of more
efinitive data, include a more rapid resolution of congestive
ymptoms; relief of anginal symptoms while awaiting cor-
nary intervention; control of hypertension complicating
F; and, in conjunction with ongoing hemodynamic mon-
toring while the intravenous drug is administered, improve-
ent of hemodynamic abnormalities prior to instituting oral
F medications.
.5.2.3. INOTROPES
atients presenting with either predominantly low output
yndrome (e.g., symptomatic hypotension) or combined
ongestion and low output may be considered for intrave-
ous inotropes such as dopamine, dobutamine, and milri-
one. These agents may help relieve symptoms due to poor
erfusion and preserve end-organ function in patients with
evere systolic dysfunction and dilated cardiomyopathy.
notropic agents are of greatest value in patients with
elative hypotension and intolerance or no response to
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April 14, 2009:1343–82 2009 Guideline Focused Update on Heart Failureasodilators and diuretics. Clinicians should be cautioned
gain that the use of these drugs portends a very poor
rognosis for their patients; a thorough hemodynamic
ssessment must be undertaken to ensure that the low
utput syndrome is responsible for the presenting clinical
igns and symptoms. Likewise, clinicians should not use a
pecific blood pressure value that might or might not mean
ypotension, to dictate the use of inotropic agents. Rather,
depressed blood pressure associated with signs of poor
ardiac output or hypoperfusion (e.g., cold clammy skin,
ool extremities, decreased urine output, altered mentation)
hould prompt a consideration for more aggressive intrave-
ous therapy. Dobutamine requires the beta-receptor for its
notropic effects, while milrinone does not. This may be a
ignificant consideration for patients already maintained on
eta-blocking drugs. Furthermore, milrinone has vasodilat-
ng properties for both the systemic circulation and the
ulmonary circulation. Despite these considerations, there is
o evidence of benefit for routine use of inotropic support in
atients presenting with acute HF due to congestion only
249,295–297). Indeed, data from several studies suggest an
ncrease in adverse outcomes when inotropes are used.
hus, inotropes should be confined to carefully selected
atients with low blood pressure and reduced cardiac output
ho can have blood pressure and heart rhythm monitored
losely (see Section 4.4.3., Intravenous Peripheral Vasodi-
ators and Positive Inotropic Agents).
Routine invasive hemodynamic monitoring is not indicated
or most patients hospitalized with symptoms of worsening
F. Recent evaluations of the use of right heart catheterization
o improve outcomes have been essentially neutral with regard
o overall benefit (250,298). However, hemodynamic monitor-
ng should be strongly considered in patients whose volume
nd filling pressures are uncertain or who are refractory to
nitial therapy, particularly in those whose filling pressures and
ardiac output are unclear. Patients with clinically significant
ypotension (systolic blood pressure typically less than 90 mm
g or symptomatic low systolic blood pressure) and/or wors-
ning renal function during initial therapy might also benefit.
atients being considered for cardiac transplantation or place-
ent of a mechanical circulatory support device are also
andidates for complete right heart catheterization, a necessary
art of the initial evaluation (see Section 4.4.4., Mechanical
nd Surgical Strategies, in the full-text guideline). Invasive
emodynamic monitoring should be performed in patients
ith 1) presumed cardiogenic shock requiring escalating pres-
or therapy and consideration of mechanical support, 2) severe
linical decompensation in which therapy is limited by uncer-
ainty regarding relative contributions of elevated filling pres-
ures, hypoperfusion, and vascular tone, 3) apparent depen-
ence on intravenous inotropic infusions after initial clinical
mprovement, or 4) persistent severe symptoms despite adjust-
ent of recommended therapies. This reinforces the concept
hat right heart catheterization is best reserved for those
ituations where a specific clinical or therapeutic question
eeds to be addressed. A.5.2.4. OTHER CONSIDERATIONS
ther treatment or diagnostic strategies may be necessary for
ndividual patients after stabilization, particularly related to the
nderlying cause of the acute event. Considerations are similar
o those previously discussed in Section 3.1.3., Evaluation of
he Cause of Heart Failure. The patient hospitalized with HF
s at increased risk for thromboembolic complications and deep
enous thrombosis and should receive prophylactic anticoagu-
ation with either intravenous unfractionated heparin or sub-
utaneous preparations of unfractionated or low-molecular-
eight heparin, unless contraindicated (299).
As the hospitalized patient becomes more clinically stable
nd volume status normalizes, oral HF therapy should be
nitiated or reintroduced (see Sections 4.3.1., Patients With
educed Left Ventricular Ejection Fraction, and 4.3.2.,
atients With HF and Normal LVEF, in the full-text
uideline). Particular caution should be used when initiating
eta blockers in patients who have required inotropes during
heir hospital course or when initiating ACE inhibitors in
hose patients who have experienced marked azotemia.
uring additional hospital days, the patient should be fully
ransitioned off all intravenous therapy and oral therapy
hould be adjusted and maximized. The clinical team should
rovide further education about HF to both the patient and
amily. The treating clinicians should also reassess overall
rognosis once current functional status and precipitating
auses of the hospitalization have been determined. The
ppropriateness of discussion about advanced therapy or end
f life preferences should also be considered (see Sections
.2.4., Assessment of Prognosis, and 7, End of Life Con-
iderations, in the full-text guideline). On discharge, the
atient, the family, and the patient’s primary physician
hould be aware and supportive of the follow-up plans.
.5.3. The Hospital Discharge
o ensure safe, high-quality, and efficient care for patients
ollowing hospitalization for HF, the consistent use of
linical practice guidelines developed by the ACCF, the
HA, and the Heart Failure Society of America should be
romoted during and after the hospital stay. One critical
erformance measure for care coordination and transition is
hat of written discharge instructions or educational mate-
ial given to patient and/or caregiver at discharge to home or
uring the hospital stay addressing all of the following:
ctivity level, diet, discharge medications, follow-up ap-
ointment, weight monitoring, and what to do if symptoms
orsen (300). Education of HF patients and their families is
ritical and often complex. Failure of these patients to
nderstand how best to comply with physician’s and other
ealthcare providers’ instructions is often a cause of HF
xacerbation leading to subsequent hospital readmission.
Large registries of hospitalized HF patients suggest that
any patients are discharged before optimal volume status
s achieved, or sent home without the benefit of life-saving
herapies such as ACE/ARB and beta-blocker medications.
mong hospitals providing care for patients with HF, there
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2009 Guideline Focused Update on Heart Failure April 14, 2009:1343–82s significant individual variability in conformity to quality-
f-care indicators and clinical outcomes and a substantial
ap in overall performance (301). Patients are discharged
ithout adequate control of their blood pressure or the
entricular response to atrial fibrillation. Often, the treating
linician fails to appreciate the severity of the HF process or
elays diagnostic testing until the patient is seen as an
utpatient. These problems, and others, may account for the
igh rate of HF rehospitalizations seen in the United States.
It is, therefore, incumbent on healthcare professionals to
e certain that patients and their families have an under-
tanding of the causes of HF, prognosis, therapy, dietary
estrictions, activity, importance of compliance, and signs
nd symptoms of recurrent HF. Thorough discharge plan-
ing that includes a special emphasis on ensuring compli-
nce with an evidence-based medication regimen (241) is
ssociated with improved patient outcomes (242,302,303).
Several studies have examined the effect of providing
ore intensive delivery of discharge instructions coupled
ightly with subsequent well-coordinated follow-up care for
atients hospitalized with HF, many with positive results
112,243–245). Comprehensive discharge planning plus
ostdischarge support for older patients with HF can
ignificantly reduce readmission rates and may improve
ealth outcomes such as survival and quality of life without
ncreasing costs. A meta-analysis (246) of 18 studies repre-
enting data from 8 countries randomized 3304 older
npatients with HF to comprehensive discharge planning
lus postdischarge support or usual care. During a mean
bservation period of 8 months, fewer intervention patients
ere readmitted compared with controls. Analysis of studies
eporting secondary outcomes found a trend toward lower
ll-cause mortality, length of stay, hospital costs, and
mprovement in quality-of-life scores for patients assigned
o an intervention compared with usual care. One other
mportant study (247) focusing on hospital discharge for
atients with HF demonstrated that the addition of a
-hour, nurse educator–delivered teaching session at the
ime of hospital discharge using standardized instructions
esulted in improved clinical outcomes, increased self-care (easure adherence, and reduced cost of care. Patients
eceiving the education intervention had a lower risk of
ehospitalization or death and lower costs of care.
The importance of patient safety for all patients hospi-
alized with HF cannot be overemphasized. Meaningful
vidence has facilitated a much better understanding of the
ystems changes necessary to achieve safer care. This in-
ludes the adoption by all US hospitals of a standardized set
f 30 “Safe Practices” endorsed by the National Quality
orum (304), which overlap in many ways with the National
atient Safety Goals espoused by The Joint Commission
305). Improved communication between physicians and
urses, medication reconciliation, transitions between care
ettings, and consistent documentation are examples of
atient safety standards that should be ensured for patients
ischarged from the hospital with HF. Care information,
specially changes in orders and new diagnostic informa-
ion, must be transmitted in a timely and clearly under-
tandable form to all of the patient’s current healthcare
roviders who need that information to provide follow-up care.
Hospitalization is in and of itself an independent risk
actor for shortened survival in patients with chronic HF.
ence, appropriate levels of symptomatic relief, support,
nd palliative care for patients with chronic HF should be
ddressed as an ongoing key component of their plan of
are, especially when hospitalized with acute decompensa-
ion (306). Fortunately, most US hospitals today have direct
ccess to palliative care services (307). Good evidence exists
or the critical importance of delivering comprehensive
upportive care to these patients, including the assessment
nd treatment of dyspnea and physiological issues including
nxiety and depression (308,309).
. Treatment of Special Populations
he recommendations for hydralazine/isosorbide dinitrate in a
pecific population have been clarified in this section and in a
revious section (120,134), based on a recent multicenter trial
Table 6).
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oncomitant Disorders
.1.3. Supraventricular Arrhythmias
here have been additional trials investigating the appropriate
anagement of atrial fibrillation in patients with HF. The text
as been modified to reflect the lessons learned from these trials
see Section 4.3.1, Patients With Reduced Left Ventricular
jection Fraction). There is also an ACC/AHA/ESC guideline
n the management of atrial fibrillation (312).
The course of patients with HF is frequently complicated
y supraventricular tachyarrhythmias, which may occur
hen the myocardial disease process affects the atria or
hen the atria are distended as a result of pressure or volume
verload of the right or left ventricles. The most common
reatable atrial arrhythmia is atrial fibrillation, which affects
0% to 30% of patients with chronic HF and is associated
ith a reduction in exercise capacity and a worse long-term
rognosis (313–315).
Supraventricular tachyarrhythmias may exert adverse ef-
ects via 4 different mechanisms: 1) the loss of atrial
nhancement of ventricular filling may compromise cardiac
able 6. Updates to Section 5. Treatment of Special Populatio
2005 Guideline Recommendation 2009 Focused Upda
Updates to Section 5. Tre
C
1. The combination of a
dinitrate and hydralaz
medical regimen for H
inhibitors and beta bl
in order to improve ou
described as African A
functional class III or
benefit similarly, but
tested (120,134). (Le
roups of patients including a) high-risk ethnic
minority groups (e.g., blacks), b) groups
underrepresented in clinical trials, and c) any
groups believed to be underserved should, in
the absence of specific evidence to direct
otherwise, have clinical screening and therapy
in a manner identical to that applied to the
broader population. (Level of Evidence: B)
2. Groups of patients in
ethnic minority group
underrepresented in c
groups believed to be
the absence of specifi
otherwise, have clinic
in a manner identical
broader population (3
Evidence: B)
t is recommended that evidence-based therapy
for HF be used in the elderly patient, with
individualized consideration of the elderly
patient’s altered ability to metabolize or
tolerate standard medications. (Level of
Evidence: C)
3. It is recommended th
therapy for HF be use
with individualized co
patient’s altered abili
tolerate standard me
Evidence: C)
Cl
he addition of isosorbide dinitrate and
hydralazine to a standard medical regimen for
HF, including ACE inhibitors and beta blockers,
is reasonable and can be effective in blacks
with NYHA functional class III or IV HF. Others
may benefit similarly, but this has not yet been
tested. (Level of Evidence: A)utput; 2) the rapid heart rate may increase demand and pecrease coronary perfusion (by shortening ventricular fill-
ng time); 3) the rapidity of ventricular response may
iminish both cardiac contraction (by aggravating abnor-
alities of the force-frequency relation) (316,317) and
ardiac relaxation (318,319); and 4) the stasis of blood in the
brillating atria may predispose patients to pulmonary or
ystemic emboli. In most patients with an ischemic or
onischemic dilated cardiomyopathy, the rapidity of ven-
ricular response is more important than the loss of atrial
upport, because restoration of sinus rhythm does not result
n predictable clinical benefits (320). Rapid supraventricular
rrhythmias may actually cause a cardiomyopathy (even in
atients without an underlying contractile abnormality) or
may exacerbate a cardiomyopathy caused by another dis-
rder (321,322). Hence, the control of ventricular rate and
he prevention of thromboembolic events are essential
lements of treatment of HF in patients with an underlying
upraventricular arrhythmia (323,324). Specific care and
nitially low doses should be used when beta blockers are
nstituted to control heart rate in patients with clinical
vidence of HF decompensation. The agent previously used
n clinical practice to slow the ventricular response in
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ffectively at rest than during exercise (325,326). Hence,
igitalis does not block the excessive exercise-induced
achycardia that may limit the functional capacity of patients
ith HF (325–328). Beta blockers are more effective than
igoxin during exercise (325,327) and are preferred because
f their favorable effects on the natural history of HF
54,58,60). The combination of digoxin and beta blockers
ay be more effective than beta blockers alone for rate
ontrol. Although both verapamil and diltiazem can also
uppress the ventricular response during exercise, they can
epress myocardial function and increase the risk of wors-
ning HF, especially in patients with HF and low EF, in
hom these drugs should be avoided (329,330). If beta-
lockers are ineffective or contraindicated in patients with
trial fibrillation and HF, amiodarone may be a useful
lternative (331). Atrioventricular nodal ablation may be
eeded if tachycardia persists despite pharmacological ther-
py (169). Catheter ablation for pulmonary vein isolation
as been most effective in patients without structural heart
isease; the benefit for patients with established HF is not
nown (332–334). Regardless of the intervention used,
very effort should be made to reduce the ventricular
esponse to less than 80 to 90 bpm at rest and less than 110
o 130 bpm during moderate exercise. Anticoagulation
hould be maintained in all patients with HF and a history
f atrial fibrillation, regardless of whether sinus rhythm is
chieved, because of the high rate of silent recurrence of
trial fibrillation with its attendant embolic risk, unless a
ontraindication exists (324).
Should patients with HF and atrial fibrillation be con-
erted to and maintained in sinus rhythm? The efficacy and
afety of restoring and maintaining sinus rhythm in patients
ith atrial fibrillation were evaluated in a total of 5032
atients in 4 separate trials (335). Both strategies for the
anagement of atrial fibrillation, either to restore and
aintain sinus rhythm by electrical or pharmacologic con-
ersion, or to control ventricular rate in atrial fibrillation,
ave been shown to have equivalent outcomes. These results
ere confirmed in 2007 with the conclusion of a large trial
f patients with both atrial fibrillation and HF (123,124,
24). Most patients revert to atrial fibrillation within a short
ime unless they are treated with a Class I or III antiar-
hythmic drug (313). However, patients with HF are not
ikely to respond favorably to Class I drugs and may be
articularly predisposed to their cardiodepressant and proar-
hythmic effects (90,146), which can increase the risk of
eath (88,89,170). Class III antiarrhythmic agents (e.g.,
otalol, dofetilide, and amiodarone) can maintain sinus
hythm in some patients, but treatment with these drugs is
ssociated with an increased risk of organ toxicity (amioda-
one) (336,337) and proarrhythmia (dofetilide) (147). Most
atients who had thromboembolic events, regardless of the
trategy used, were in atrial fibrillation at the time of the
vent and either were not undergoing anticoagulation ther-
py or were undergoing therapy at subtherapeutic levels.hus, it is reasonable to treat HF patients with atrial
brillation with a strategy of either scrupulous rate control
r an attempt at rhythm control.
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